Jan Please

Access DB# 107746

SEARCH REQUEST FORM

Scientific and Technical Inf rmation Center

Requester's Full Name: S. Kumar Examiner #: 69594 Date: 11/5/03
Art Unit: 1621 Phone Number 308-4519 Serial Number: 09/998,195
Mail Box and Bldg/Room Location: CM1 7A07 7E32 Results Format Preferred (circle): PAPER DISK E-MAIL

If mor than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Synthesis, methods of using, and composition of hydroxylated cyclobutylalkylamines

Inventors (please provide full names): Chris H. Senanayake et al.

Earliest Priority Filing Date: _____

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*



Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

R_1 & R_2 are H or alkyl

R_3 R_4, R_5 are H, OH, alkoxy provided that at least one of R_3, R_4 and R_5 is not hydrogen. if each of R_1, R_2, R_4, R_5 is hydrogen and then R_3 is is OH, the compound is not racemic and if each R_1, R_2, R_3 and R_4 is hydrogen & R_5 is OH, the compound is not racemic

Use: treatment and prevention of diseases and or disorders that are ameliorated by the inhibition of neuronal monoamine uptake in mammals.

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Jan	NA Sequence (#)	STN ✓
Searcher Phone #: 4498	AA Sequence (#)	Dialog
Searcher Location:	Structure (#) ✓	Questel/Orbit
Date Searcher Picked Up: 11/7	Bibliographic	Dr.Link (STIC)
Date Completed: 11/7	Litigation	Lexis/Nexis
Searcher Prep & Review Time:	Fulltext	Sequence Systems
Clerical Prep Time: 20	Patent Family	WWW/Internet
Online Time: 450	Other	Other (specify)

RECEIVED NOV -5 2003

PTO-1590 (8-01)

STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 107746

TO: Shailendra Kumar **Location: 7a07 / 7e12** **Friday, November 07, 2003** **Art Unit: 1621** **Phone: 308-4519** **Serial Number: 09 / 998195**	**From: Jan Delaval** **Location: Biotech-Chem Library** **CM1-1E07** **Phone: 308-4498** **jan.delaval@uspto.gov**

Search Notes

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 16:35:55 ON 07 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    6 NOV 2003  HIGHEST RN 613649-12-0
DICTIONARY FILE UPDATES:   6 NOV 2003  HIGHEST RN 613649-12-0

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l10
L3                STR
```



Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov

```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   7   3
NUMBER OF NODES IS  15

STEREO ATTRIBUTES: NONE
L5          425 SEA FILE=REGISTRY SSS FUL L3
L8              STR
```



```
VAR G1=NH2/21/23
VAR G2=H/OH/33
VAR G3=CH2/37
VAR G4=OH/33
VAR G5=CH3/40
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT   IS MCY  UNS  AT  29
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS E4 C  AT  28
ECOUNT  IS E6 C  AT  29

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  21

STEREO ATTRIBUTES: NONE
L10          82 SEA FILE=REGISTRY SUB=L5 CSS FUL L8

100.0% PROCESSED    425 ITERATIONS                          82 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 15:47:32 ON 07 NOV 2003)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 15:47:42 ON 07 NOV 2003
L1             STR
L2          20 S L1
L3             STR L1
L4          20 S L3
L5         425 S L3 FUL
               SAV L5 KUMAR998/A
L6             STR L3
L7           7 S L6 CSS SAM SUB=L5
L8             STR L6
L9           7 S L8 CSS SAM SUB=L5
L10         82 S L8 CSS FUL SUB=L5
               SAV L10 KUMAR998A/A
L11         64 S L10 AND O/ELS
L12         47 S L11 AND 1/O
L13         27 S L12 AND C15H22CLNO
L14         12 S L13 AND 1/NC
               SEL RN 1 2
L15         10 S L14 NOT E1-E2
L16         29 S L10 AND 1/NC
L17         19 S L16 NOT L15
L18         29 S L15,L17
               SEL RN
L19         50 S E3-E31/CRN
L20          3 S L10 NOT L15,L18,L19
L21         53 S L10 NOT L16

     FILE 'HCAOLD' ENTERED AT 16:04:45 ON 07 NOV 2003
L22          0 S L15
L23          0 S L21

     FILE 'HCAPLUS' ENTERED AT 16:04:53 ON 07 NOV 2003
L24          2 S L15
```

```
L25          100 S L21
L26            2 S L24 AND L25
L27           98 S L25 NOT L26
                 E SENANAYAKE C/AU
L28          129 S E3,E6,E10-E12,E15,E16,E17
                 E RUBIN P/AU
L29          142 S E3,E5,E13,E14
                 E JERUSSI T/AU
L30           59 S E4,E5
                 E SEPRACOR/PA,CS
L31          374 S E3,E4
L32           14 S L24-L27 AND L28-L31
L33           85 S L24-L27,L32 AND (PY<=2000 OR PRY<=2000 OR AY<=2000)
L34          100 S L24-L27,L32-L33
L35          355 S SIBUTRAMINE
L36          231 S L34,L35 AND (PY<=2000 OR PRY<=2000 OR AY<=2000)
L37           77 S L35 AND (MONOAMINE OR MAO)

     FILE 'REGISTRY' ENTERED AT 16:28:10 ON 07 NOV 2003

     FILE 'HCAPLUS' ENTERED AT 16:28:51 ON 07 NOV 2003
L38          319 S L10
L39          234 S L34,L35,L38 AND (PY<=2000 OR PRY<=2000 OR AY<=2000)
L40           67 S L39 AND (MONOAMINE OR MAO)
                 E MONOAMINE/CT
                 E E20+ALL
L41           77 S E3 (L) (UPTAKE OR REUPTAKE)
L42           29 S L39 AND L41
L43           79 S E3 (L) INHIBIT?
L44           10 S L43 AND L39
L45           29 S L42,L44
                 E MONOAMINE/CT
                 E E15+ALL
L46          227 S E2
L47          236 S E4
L48          217 S E6
L49           45 S E8
L50          180 S E10
L51            4 S L46-L50 AND L39
L52           32 S L45,L51
L53           30 S L52 AND L38
L54           20 S L28-L31 AND L38,L35
L55           13 S L54 AND L39
L56           41 S L53,L55
L57            7 S L54 NOT L56
L58           48 S L56,L57
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 16:34:30 ON 07 NOV 2003
L59           62 S E1-E62
L60            4 S L59 AND L15
L61           10 S L15,L60
L62           58 S L59 NOT L61

     FILE 'HCAPLUS' ENTERED AT 16:35:36 ON 07 NOV 2003
L63            2 S L61
L64           49 S L58,L63

     FILE 'REGISTRY' ENTERED AT 16:35:55 ON 07 NOV 2003

=> d ide can tot l15

L15  ANSWER 1 OF 10  REGISTRY  COPYRIGHT 2003 ACS on STN
```

RN 435343-79-6 REGISTRY
CN Cyclobutanol, 3-[(1R)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-77-4 REGISTRY
CN Cyclobutanol, 3-[(1S)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-75-2 REGISTRY
CN Cyclobutanol, 3-[(1R)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L15 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-65-0 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βR,δR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L15 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-63-8 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βS,δS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L15 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-60-5 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βR,δS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L15 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-58-1 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βS,δR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L15 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-90-4 REGISTRY
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L15 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-84-6 REGISTRY
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Relative stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L15 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-83-5 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF **C15 H22 Cl N O**
CI COM
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

=> s l10 not l15
L65 72 L10 NOT L15

=> d ide can tot

L65 ANSWER 1 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 586349-89-5 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, nitrate (9CI) (CA INDEX NAME)
MF C17 H26 Cl N . H N O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

CM 1

CRN 106650-56-0
CMF C17 H26 Cl N



CM 2

CRN 7697-37-2
CMF H N O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:214237

L65 ANSWER 2 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-98-9 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, hydrochloride, (αS,βR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (435343-97-8)

Absolute stereochemistry.



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 3 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-97-8 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, (αS,βR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 4 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-96-7 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, hydrochloride, (αR,βR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (435343-95-6)

Absolute stereochemistry.



HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 5 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-95-6 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, (αR,βR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 6 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-94-5 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, hydrochloride, (αR,βS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 7 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-93-4 REGISTRY
CN Cyclobutaneethanol, β-amino-1-(4-chlorophenyl)-α-(1-methylethyl)-, hydrochloride, (αS,βS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 8 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-89-8 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αS)-, compd. with cis-3-(4-chlorophenyl)-3-[(1S)-3-methyl-1-(methylamino)butyl]cyclobutanol (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C8 H8 O3

SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-81-0
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 17199-29-0
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 9 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-88-7 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with cis-3-(4-chlorophenyl)-3-[(1R)-3-methyl-1-(methylamino)butyl]cyclobutanol (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C8 H8 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-87-6
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 611-71-2
CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 10 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-87-6 REGISTRY
CN Cyclobutanol, 3-(4-chlorophenyl)-3-[(1R)-3-methyl-1-(methylamino)butyl]-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L65 ANSWER 11 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-86-5 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αS)-, compd. with trans-3-(4-chlorophenyl)-3-[(1S)-3-methyl-1-(methylamino)butyl]cyclobutanol (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C16 H24 Cl N O . C8 H8 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-85-4
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 17199-29-0
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 12 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-85-4 REGISTRY
CN Cyclobutanol, 3-(4-chlorophenyl)-3-[(1S)-3-methyl-1-(methylamino)butyl]-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L65 ANSWER 13 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-84-3 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with trans-3-(4-chlorophenyl)-3-[(1R)-3-methyl-1-(methylamino)butyl]cyclobutanol (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C8 H8 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-83-2
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 611-71-2
CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 14 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-83-2 REGISTRY
CN Cyclobutanol, 3-(4-chlorophenyl)-3-[(1R)-3-methyl-1-(methylamino)butyl]-, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 15 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-82-1 REGISTRY
CN Cyclobutanol, 3-(4-chlorophenyl)-3-[(1S)-3-methyl-1-(methylamino)butyl]-, cis-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-81-0
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 16 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-81-0 REGISTRY
CN Cyclobutanol, 3-(4-chlorophenyl)-3-[(1S)-3-methyl-1-(methylamino)butyl]-, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L65 ANSWER 17 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-80-9 REGISTRY
CN Cyclobutanol, 3-[(1R)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, cis-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-79-6
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 18 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-78-5 REGISTRY
CN Cyclobutanol, 3-[(1S)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, trans-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-77-4
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 19 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-76-3 REGISTRY
CN Cyclobutanol, 3-[(1R)-1-amino-3-methylbutyl]-3-(4-chlorophenyl)-, trans-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-75-2
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 20 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-74-1 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βR,δR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-73-0
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 21 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-73-0 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βR,δR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 22 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-72-9 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βS,δS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-71-8
CMF C16 H24 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 23 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-71-8 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βS,δS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 24 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-70-7 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, hydrochloride, (βR,δS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (435343-69-4)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 25 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-69-4 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βR,δS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 26 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-68-3 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, hydrochloride, (βS,δR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
CRN (435343-67-2)

Absolute stereochemistry.



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 27 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-67-2 REGISTRY
CN Cyclobutanebutanol, 1-(4-chlorophenyl)-β-methyl-δ-(methylamino)-, (βS,δR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N O
CI COM
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 28 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-66-1 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βR,δR)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-65-0
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 29 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-64-9 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βS,δS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-63-8
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 30 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-61-6 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βR,δS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA

LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-60-5
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 31 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 435343-59-2 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, (βS,δR)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 435343-58-1
CMF C15 H22 Cl N O

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:20209

L65 ANSWER 32 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 433305-28-3 REGISTRY
CN Butanedioic acid, 2,3-bis(phenylmethoxy)-, (2S,3S)-, compd. with (αR)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 O6 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CM 1

CRN 154752-44-0
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 116679-01-7
CMF C18 H18 O6

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:5981

L65 ANSWER 33 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 391905-99-0 REGISTRY
CN Butanedioic acid, 2,3-bis(phenylmethoxy)-, (2R,3R)-, compd. with (αS)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 O6 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 153341-22-1
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 138794-81-7
CMF C18 H18 O6

Absolute stereochemistry. Rotation (-).



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:5981

REFERENCE 2: 136:139829

L65 ANSWER 34 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 391682-39-6 REGISTRY
CN Butanedioic acid, 2,3-bis(phenylmethoxy)-, (2R,3R)-, compd. with (αR)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C18 H18 O6 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 154752-44-0
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 138794-81-7
CMF C18 H18 O6

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:139829

L65 ANSWER 35 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 389056-74-0 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-57-0
CMF C15 H22 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:325227

REFERENCE 2: 136:139829

REFERENCE 3: 136:96093

L65 ANSWER 36 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 389056-73-9 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 84467-54-9
CMF C15 H22 Cl N



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:139829

REFERENCE 2: 136:96093

L65 ANSWER 37 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 389056-70-6 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-56-9
CMF C15 H22 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:325227

REFERENCE 2: 136:139829

REFERENCE 3: 136:96093

L65 ANSWER 38 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350701-71-2 REGISTRY
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (αS)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αS)-, (2R,3R)-2,3-bis(benzoyloxy)butanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C18 H14 O8 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 153341-22-1
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 2743-38-6
CMF C18 H14 O8

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:122299

L65 ANSWER 39 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 350502-77-1 REGISTRY
CN Formic acid, compd. with 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, formate (9CI)
MF C17 H26 Cl N . C H2 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 106650-56-0
CMF C17 H26 Cl N



CM 2

CRN 64-18-6
CMF C H2 O2



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:111957

L65 ANSWER 40 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 286402-50-4 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, monohydrate (9CI) (CA INDEX NAME)
MF C17 H26 Cl N . H2 O
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER
CRN (106650-56-0)



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:129893

L65 ANSWER 41 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 262854-36-4 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, USPATFULL
CRN (229639-57-0)

Absolute stereochemistry. Rotation (-).



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:256009

L65 ANSWER 42 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 262854-35-3 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, USPATFULL
CRN (229639-56-9)

Absolute stereochemistry. Rotation (+).



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:256009

L65 ANSWER 43 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 260402-77-5 REGISTRY
CN Butanedioic acid, 2,3-bis(benzoyloxy)-, (2S,3S)-, compd. with (αR)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αR)-, (2S,3S)-2,3-bis(benzoyloxy)butanedioate (1:1)

(9CI)
FS STEREOSEARCH
MF C18 H14 O8 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 154752-44-0
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 17026-42-5
CMF C18 H14 O8

Absolute stereochemistry. Rotation (+).



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 135:122299

REFERENCE 2: 132:207624

L65 ANSWER 44 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259731-40-3 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (R)-Desmethylsibutramine hydrochloride
FS STEREOSEARCH
MF C16 H24 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CRN (229639-54-7)

Absolute stereochemistry. Rotation (+).



● HCl

8 REFERENCES IN FILE CA (1907 TO DATE)
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:262796

REFERENCE 2: 137:5981

REFERENCE 3: 136:139829

REFERENCE 4: 136:96093

REFERENCE 5: 135:122299

REFERENCE 6: 132:256009

REFERENCE 7: 132:207624

REFERENCE 8: 132:189679

L65 ANSWER 45 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259731-39-0 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (S)-Desmethylsibutramine hydrochloride
FS STEREOSEARCH
MF C16 H24 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL
CRN (229639-55-8)

Absolute stereochemistry. Rotation (-).



● HCl

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:262796

REFERENCE 2: 137:5981

REFERENCE 3: 136:139829

REFERENCE 4: 136:96093

REFERENCE 5: 135:122299

REFERENCE 6: 132:256009

REFERENCE 7: 132:189679

L65 ANSWER 46 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-95-8 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αS)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-57-0
CMF C15 H22 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:5981

REFERENCE 2: 136:139829

REFERENCE 3: 136:96093

REFERENCE 4: 135:122299

REFERENCE 5: 132:189679

L65 ANSWER 47 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-93-6 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αR)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, CASREACT, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-56-9
CMF C15 H22 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:39012

REFERENCE 2: 137:5981

REFERENCE 3: 136:96093

REFERENCE 4: 135:122299

REFERENCE 5: 132:189679

L65 ANSWER 48 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-92-5 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C15 H22 Cl N . C4 H6 O6
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 84467-54-9
CMF C15 H22 Cl N



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:5981

REFERENCE 2: 136:139829

REFERENCE 3: 135:122299

REFERENCE 4: 132:189679

L65 ANSWER 49 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-91-4 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αS)-, compd. with (αS)-1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, (αS)-, (αS)-α-hydroxybenzeneacetate (9CI)
FS STEREOSEARCH
MF C16 H24 Cl N . C8 H8 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-55-8
CMF C16 H24 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 17199-29-0
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).



6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:262796

REFERENCE 2: 137:5981

REFERENCE 3: 136:139829

REFERENCE 4: 136:96093

REFERENCE 5: 135:122299

REFERENCE 6: 132:189679

L65 ANSWER 50 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-90-3 REGISTRY
CN Benzeneacetic acid, α-hydroxy-, (αR)-, compd. with (αR)-1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, (αR)-, (αR)-α-hydroxybenzeneacetate (9CI)
FS STEREOSEARCH
MF C16 H24 Cl N . C8 H8 O3
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 229639-54-7
CMF C16 H24 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 611-71-2
CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).



6 REFERENCES IN FILE CA (1907 TO DATE)
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:262796

REFERENCE 2: 137:5981

REFERENCE 3: 136:139829

REFERENCE 4: 136:96093

REFERENCE 5: 135:122299

REFERENCE 6: 132:189679

L65 ANSWER 51 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-88-9 REGISTRY
CN Butanedioic acid, 2,3-dihydroxy-, bis(phenylmethyl) ester, (2S,3S)-, compd. with (αR)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αR)-, compd. with bis(phenylmethyl) (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C18 H18 O6 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 154752-44-0
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (+).



CM 2

CRN 4136-22-5
CMF C18 H18 O6

Absolute stereochemistry. Rotation (-).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:189679

L65 ANSWER 52 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 259729-87-8 REGISTRY
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, bis(phenylmethyl) ester, compd. with (αS)-1-(4-chlorophenyl)-N,N-dimethyl-α-(2-

methylpropyl)cyclobutanemethanamine (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αS)-, compd. with bis(phenylmethyl) (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI)
FS STEREOSEARCH
MF C18 H18 O6 . C17 H26 Cl N
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 153341-22-1
CMF C17 H26 Cl N

Absolute stereochemistry. Rotation (-).



CM 2

CRN 622-00-4
CMF C18 H18 O6

Absolute stereochemistry. Rotation (+).



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:189679

L65 ANSWER 53 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 229639-57-0 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αS)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-Didesmethylsibutramine
FS STEREOSEARCH
MF C15 H22 Cl N
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

40 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
40 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 138:39012

REFERENCE 4: 137:325227

REFERENCE 5: 137:242205

REFERENCE 6: 137:5981

REFERENCE 7: 136:139829

REFERENCE 8: 136:96093

REFERENCE 9: 135:205587

REFERENCE 10: 135:190433

L65 ANSWER 54 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 229639-56-9 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, (αR)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Didesmethylsibutramine
FS STEREOSEARCH
MF C15 H22 Cl N
CI COM
SR CA
LC STN Files: CA, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
41 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 138:39012

REFERENCE 4: 137:325227

REFERENCE 5: 137:242205

REFERENCE 6: 137:169260

REFERENCE 7: 137:5981

REFERENCE 8: 136:139829

REFERENCE 9: 136:96093

REFERENCE 10: 135:205587

L65 ANSWER 55 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 229639-55-8 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 C1 N
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

38 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
38 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 137:242205

REFERENCE 4: 137:5981

REFERENCE 5: 136:139829

REFERENCE 6: 136:96093

REFERENCE 7: 135:205587

REFERENCE 8: 135:190433

REFERENCE 9: 135:122299

REFERENCE 10: 134:320858

L65 ANSWER 56 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 229639-54-7 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C16 H24 Cl N
CI COM
SR CA
LC STN Files: CA, CAPLUS, DRUGNL, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

37 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
37 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 137:242205

REFERENCE 4: 136:139829

REFERENCE 5: 136:96093

REFERENCE 6: 135:205587

REFERENCE 7: 135:190433

REFERENCE 8: 135:122299

REFERENCE 9: 134:320858

REFERENCE 10: 133:261533

L65 ANSWER 57 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-92-6 REGISTRY
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, cis-, (2E)-2-butenedioate (10:9) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, cis-, (E)-2-butenedioate (10:9) (salt)
FS STEREOSEARCH
MF C15 H22 Cl N O . 9/10 C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 186521-90-4
CMF C15 H22 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L65 ANSWER 58 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-91-5 REGISTRY
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, cis-,

(2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, cis-, (E)-2-butenedioate (1:1) (salt)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 186521-90-4
CMF C15 H22 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L65 ANSWER 59 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-89-1 REGISTRY
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, trans-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Cyclobutanol, 3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)-, trans-, (E)-2-butenedioate (1:1) (salt)
FS STEREOSEARCH
MF C15 H22 Cl N O . C4 H4 O4
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 186521-84-6
CMF C15 H22 Cl N O

Relative stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L65 ANSWER 60 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 186521-88-0 REGISTRY
CN Cyclobutanebutanol, δ-amino-1-(4-chlorophenyl)-β-methyl-, hydrochloride (9CI) (CA INDEX NAME)
MF C15 H22 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS
CRN (186521-83-5)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:143907

L65 ANSWER 61 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 168835-59-4 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Desmethylsibutramine

CN N-Monodemethylsibutramine
FS 3D CONCORD
MF C16 H24 Cl N
CI COM
SR CA
LC STN Files: CA, CAPLUS, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41 REFERENCES IN FILE CA (1907 TO DATE)
21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
41 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 137:242205

REFERENCE 4: 137:5981

REFERENCE 5: 136:139829

REFERENCE 6: 136:96093

REFERENCE 7: 135:205587

REFERENCE 8: 135:190433

REFERENCE 9: 135:122299

REFERENCE 10: 134:320858

L65 ANSWER 62 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 154752-45-1 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Sibutramine hydrochloride
FS STEREOSEARCH
MF C17 H26 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, USPATFULL
CRN (154752-44-0)

Absolute stereochemistry. Rotation (+).



● HCl

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:314607

REFERENCE 2: 135:122299

REFERENCE 3: 132:256009

REFERENCE 4: 132:207624

REFERENCE 5: 120:280290

L65 ANSWER 63 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 154752-44-0 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αR)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (+)-Sibutramine
CN (R)-Sibutramine
FS STEREOSEARCH
MF C17 H26 Cl N
CI COM
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, DRUGPAT, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

41 REFERENCES IN FILE CA (1907 TO DATE)
41 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:314607

REFERENCE 2: 138:83403

REFERENCE 3: 138:66716

REFERENCE 4: 137:242205

REFERENCE 5: 137:169260

REFERENCE 6: 136:139829

REFERENCE 7: 136:96093

REFERENCE 8: 136:96083

REFERENCE 9: 135:205587

REFERENCE 10: 135:190433

L65 ANSWER 64 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 153341-23-2 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-Sibutramine hydrochloride
FS STEREOSEARCH
MF C17 H26 Cl N . Cl H
SR CA
LC STN Files: CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL
CRN (153341-22-1)

Absolute stereochemistry. Rotation (-).



● HCl

9 REFERENCES IN FILE CA (1907 TO DATE)
9 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:5981

REFERENCE 2: 136:139829

REFERENCE 3: 136:96093

REFERENCE 4: 136:96083

REFERENCE 5: 135:122299

REFERENCE 6: 132:256009

REFERENCE 7: 132:207624

REFERENCE 8: 132:189679

REFERENCE 9: 120:144170

L65 ANSWER 65 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 153341-22-1 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, (αS)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (-)-sibutramine
FS STEREOSEARCH
MF C17 H26 Cl N
CI COM
SR CA
LC STN Files: ADISNEWS, CA, CAPLUS, CIN, DRUGNL, DRUGPAT, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

38 REFERENCES IN FILE CA (1907 TO DATE)
38 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 137:242205

REFERENCE 4: 137:5981

REFERENCE 5: 136:139829

REFERENCE 6: 136:96093

REFERENCE 7: 135:205587

REFERENCE 8: 135:190433

REFERENCE 9: 135:122299

REFERENCE 10: 134:320858

L65 ANSWER 66 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 125494-59-9 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride, monohydrate (9CI) (CA INDEX NAME)

OTHER NAMES:
CN Sibutramine hydrochloride monohydrate
MF C17 H26 Cl N . Cl H . H2 O
SR US Adopted Names Council
LC STN Files: CA, CAPLUS, CHEMCATS, CSCHEM, DRUGNL, DRUGPAT, DRUGUPDATES, IPA, MRCK*, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
CRN (106650-56-0)



● HCl

● H_2O

40 REFERENCES IN FILE CA (1907 TO DATE)
40 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:83403

REFERENCE 2: 138:66716

REFERENCE 3: 137:242205

REFERENCE 4: 135:205587

REFERENCE 5: 135:111957

REFERENCE 6: 134:320858

REFERENCE 7: 134:76405

REFERENCE 8: 134:76403

REFERENCE 9: 133:261533

REFERENCE 10: 133:247297

L65 ANSWER 67 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 106650-56-0 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Medaria
CN Meridia
CN Sibutramine
FS 3D CONCORD

MF C17 H26 Cl N
CI COM
SR World Health Organization
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PIRA, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

279 REFERENCES IN FILE CA (1907 TO DATE)
27 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
281 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:307686

REFERENCE 2: 139:255389

REFERENCE 3: 139:255308

REFERENCE 4: 139:250286

REFERENCE 5: 139:207676

REFERENCE 6: 139:206752

REFERENCE 7: 139:206736

REFERENCE 8: 139:197489

REFERENCE 9: 139:191120

REFERENCE 10: 139:190346

L65 ANSWER 68 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 106080-04-0 REGISTRY
CN Cyclobutaneethanol, 1-(4-chlorophenyl)-β-(dimethylamino)-α-(1-methylethyl)-, hydrochloride (9CI) (CA INDEX NAME)
MF C17 H26 Cl N O . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 106:119342

L65 ANSWER 69 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 84485-00-7 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BTS 54524
CN Reductil
CN Sibutramine hydrochloride
DR 111394-01-5
MF C17 H26 Cl N . Cl H
LC STN Files: ANABSTR, BIOBUSINESS, BIOSIS, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DIOGENES, DRUGPAT, DRUGUPDATES, IPA, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
CRN (106650-56-0)



● HCl

72 REFERENCES IN FILE CA (1907 TO DATE)
72 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:185847

REFERENCE 2: 139:12247

REFERENCE 3: 138:83403

REFERENCE 4: 138:66716

REFERENCE 5: 137:288261

REFERENCE 6: 137:129878

REFERENCE 7: 137:109489

REFERENCE 8: 137:5981

REFERENCE 9: 136:401475

REFERENCE 10: 136:355482

L65 ANSWER 70 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 84484-78-6 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:
CN BTS 54-505
MF C15 H22 Cl N . Cl H
LC STN Files: BIOSIS, CA, CAPLUS, CHEMCATS, MEDLINE, TOXCENTER, USPATFULL
CRN (84467-54-9)



● HCl

16 REFERENCES IN FILE CA (1907 TO DATE)
16 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:348533

REFERENCE 2: 138:331532

REFERENCE 3: 137:242205

REFERENCE 4: 137:57355

REFERENCE 5: 136:355061

REFERENCE 6: 132:256009

REFERENCE 7: 132:49773

REFERENCE 8: 129:326027

REFERENCE 9: 126:143907

REFERENCE 10: 124:250580

L65 ANSWER 71 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 84467-94-7 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-N-methyl-α-(2-methylpropyl)-, hydrochloride (9CI) (CA INDEX NAME)
OTHER NAMES:

CN BTS 54-354
CN Desmethylsibutramine hydrochloride
MF C16 H24 Cl N . Cl H
LC STN Files: CA, CAPLUS, DDFU, DRUGNL, DRUGU, DRUGUPDATES, TOXCENTER, USPAT2, USPATFULL
CRN (168835-59-4)



● HCl

15 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 137:57355

REFERENCE 2: 137:5981

REFERENCE 3: 136:139829

REFERENCE 4: 136:96093

REFERENCE 5: 135:122299

REFERENCE 6: 132:256009

REFERENCE 7: 132:189679

REFERENCE 8: 129:326027

REFERENCE 9: 126:143907

REFERENCE 10: 124:250580

L65 ANSWER 72 OF 72 REGISTRY COPYRIGHT 2003 ACS on STN
RN 84467-54-9 REGISTRY
CN Cyclobutanemethanamine, 1-(4-chlorophenyl)-α-(2-methylpropyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN (±)-Didesmethylsibutramine
CN N-Didemethylsibutramine
FS 3D CONCORD
MF C15 H22 Cl N
CI COM
LC STN Files: CA, CAPLUS, CASREACT, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

55 REFERENCES IN FILE CA (1907 TO DATE)
20 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
55 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:237576

REFERENCE 2: 138:214796

REFERENCE 3: 138:83403

REFERENCE 4: 138:66716

REFERENCE 5: 137:242205

REFERENCE 6: 137:169260

REFERENCE 7: 137:5981

REFERENCE 8: 136:401475

REFERENCE 9: 136:355061

REFERENCE 10: 136:183562

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 16:37:02 ON 07 NOV 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 7 Nov 2003 VOL 139 ISS 20
FILE LAST UPDATED: 6 Nov 2003 (20031106/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d l64 bib abs hitrn retable tot

L64 ANSWER 1 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:221497 HCAPLUS
DN 138:231788
TI Methods of preparing and using 2-hydroxy derivatives of **sibutramine** and its metabolites
IN **Senanayake, Chris H.**; **Jerussi, Thomas P.**; Currie, Mark G.; Fang, Qun K.; Hsu, Bob
PA **Sepracor** Inc., USA
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003022259	A1	20030320	WO 2002-US29014	20020912
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003087963	A1	20030508	US 2002-238630	20020911
PRAI US 2001-318672P	P	20010913		
US 2001-325192P	P	20010928		

OS MARPAT 138:231788
AB The invention is directed, in part, to racemic and stereomerically pure 2-hydroxy derivs. of **sibutramine** and its metabolites, and 2-hydroxy derivs. of desmethylsibutramine and didesmethylsibutramine in particular. Methods of preparing these derivs. are also disclosed. The invention is also directed to pharmaceutical compns. and dosage forms that comprise therapeutically or prophylactically effective amts. of the compds., optionally in combination with an addnl. pharmacol. active compound These pharmaceutical compns. and dosage forms can be used in the methods of the invention, which provide for the treatment or prevention of a variety of diseases and disorders.
IT **106650-56-0D, Sibutramine,** derivs.
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and **sibutramine** metabolite hydroxy derivative preparation, pharmaceutical compns., and therapeutic use)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Housley	1991			US 5047432	HCAPLUS

L64 ANSWER 2 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:43023 HCAPLUS
DN 138:83403
TI **Sibutramine** and related compounds for weight loss after pregnancy
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA USA
SO U.S. Pat. Appl. Publ., 5 pp.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
PI	US 2003013735	A1	20030116		US 2000-528801	20000317 <--
PRAI	US 2000-528801		20000317	<--		

GI



I

AB A compound I (R1, R2 = H, Me), or a pharmaceutically acceptable salt thereof (e.g. N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride (**sibutramine** hydrochloride), optionally in the form of its monohydrate), is used for aiding weight loss after pregnancy.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7** , **Sibutramine** hydrochloride **106650-56-0**, **Sibutramine 106650-56-0D**, **Sibutramine**, enantiomers **125494-59-9**, **Sibutramine** hydrochloride monohydrate **153341-22-1**, (-)-**Sibutramine** **154752-44-0**, (+)-**Sibutramine 168835-59-4** **168835-59-4D**, enantiomers **229639-54-7** **229639-55-8 229639-56-9 229639-57-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and related compds. for weight loss after pregnancy)

L64 ANSWER 3 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:814093 HCAPLUS
DN 137:325227
TI Preparation of didesmethylsibutramine and other **sibutramine** derivatives
IN **Senanayake, Chris Hugh**; Han, Zhengxu; Krishnamurthy, Dhileepkumar; Pflum, Derek
PA **Sepracor**, Inc., USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002083631	A1	20021024	WO 2002-US11469	20020412
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002183554	A1	20021205	US 2002-120503	20020412

US 6610887 B2 20030826
PRAI US 2001-283371P P 20010413
GI



I

AB **Sibutramine** derivs. [e.g., didesmethylsibutramine (I)] were prepared For example, 1-(4-chlorophenyl)-cyclobutane-carboxaldehyde was reacted with t-butylsulfinamde to give 98% (R)-N-[1-(4-chlorophenyl)-cyclobutylmethylidene-2-Me propane] sulfinamide, which was reacted with i-BuLi in the presence of BF3•OEt2 to give 85% (R)-I. The effect of varying the Lewis acid/Lewis base was also studied.

IT **389056-70-6P 389056-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **229639-56-9P 229639-57-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of didesmethylsibutramine)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bailety	2001			US 6174925 B1	HCAPLUS
Scheinbaum	1995			US 5436272 A	HCAPLUS

L64 ANSWER 4 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:808777 HCAPLUS
DN 138:237576
TI Novel diacid accelerated borane reducing agent for imines
AU Lu, Zhi-Hui; Bhongle, Nandkumar; Su, Xiping; Ribe, Seth; **Senanayake, Chris H.**
CS Chemical Process R&D, **Sepracor**, Inc., Marlborough, MA, 01752, USA
SO Tetrahedron Letters (2002), 43(47), 8617-8620
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 138:237576
AB A remarkable effect of diacids in modulating the reactivity of borane has been discovered. This novel process provides a rapid and excellent access for reduction of a variety of imines with different functionalities.

IT **84467-54-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(effect of borane reducing agents/diacid accelerators systems on chemoselective reduction of imines)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Anon				Reductions in Organi	
Anon				Reductions in Organi	
Anon	1975		135	Synthesis	
Anon	1985		1609	The Sigma-Aldrich Li	
Borner, A	1993	4	2219	Tetrahedron: Asymmet	
Brown, H	1977	99	8218	J Am Chem Soc	HCAPLUS
Brwon, H	1982	47	3153	J Org Chem	
Brwon, H	1975			Organic Synthesis vi	
Buckett, W	1988	12	575	Prog Neuropsychophar	HCAPLUS
Chen, G	2002	122	4217	J Am Chem Soc	
Fields, L	1993	4	2229	Tetrahedron: Asymmet	HCAPLUS
Hola, J	1997		983	Synthesis	
Jerussi, T	2001			PCT Appl 20020010198	
Knettle, B	2001	3	2321	Org Lett	HCAPLUS
Lane, C	1974	39	3052	J Org Chem	HCAPLUS
Shibata, I				No publication given	
Shimizu, M	2001		792	Chem Lett	HCAPLUS
Sibi, M	1999	40	2477	Tetrahedron Lett	HCAPLUS
Steinhagen, H	1996	35	2339	Angew Chem, Int Ed	HCAPLUS
Sugiyama, E	1998	63	383	J Org Chem	
Ward, J	1992	3	849	Tetrahedron: Asymmet	HCAPLUS
Williams, D	1997		523	Synlett	HCAPLUS

L64 ANSWER 5 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:794480 HCAPLUS
DN 138:39012
TI First Application of Tunable Alkyl or Aryl Sulfinamides to the Stereoselective Synthesis of a Chiral Amine: Asymmetric Synthesis of (R)-Didesmethylsibutramine ((R)-DDMS) Using (R)-Triethylmethylsulfinamide ((R)-TESA)
AU Han, Zhengxu; Krishnamurthy, Dhileepkumar; Pflum, Derek; Grover, Paul; Wald, Stephen A.; **Senanayake, Chris H.**
CS Chemical Process Research and Development, **Sepracor** Inc., Marlborough, MA, 01752, USA
SO Organic Letters (2002), 4(23), 4025-4028
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:39012
GI



I

AB A highly diastereoselective addition of i-BuLi to a triethylmethylsulfinamide derived aldimine was used as the key step in the first asym. synthesis of (R)-didesmethylsibutramine (I), a metabolite of **sibutramine** for the potential treatment of CNS disorders.
IT **229639-56-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of didesmethylsibutramine via addition of iso-Bu

amine to chiral alkyl or aryl sulfinamides)
IT **229639-57-0P 259729-93-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of didesmethylsibutramine via addition of iso-Bu
amine to chiral alkyl or aryl sulfinamides)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Barrow, J	2001	42	2051	Tetrahedron Lett	HCAPLUS
Borg, G	1999	40	6709	Tetrahedron Lett	HCAPLUS
Borg, G	2001	42	1433	Tetrahedron Lett	HCAPLUS
Buckett, W	1988	12	575	Prog Neuro-Psychopha	HCAPLUS
Cogan, D	1999	55	8883	Tetrahedron	HCAPLUS
Davis, F	1998	27	13	Chem Soc Rev	HCAPLUS
Davis, F	1997	62	2555	J Org Chem	HCAPLUS
Davis, F	1999	64	3396	J Org Chem	HCAPLUS
Davis, F	2000	65	8704	J Org Chem	HCAPLUS
Davis, F	1993	34	6229	Tetrahedron Lett	HCAPLUS
Enders, D	1997	8	1895	Tetrahedron:Asymmetr	HCAPLUS
Han, Z	2002	124	7880	J Am Chem Soc	HCAPLUS
Jerussi, T	2000			WO 0010551	HCAPLUS
Kobayashi, S	1999	99	1069	Chem Rev	HCAPLUS
Krishnamurthy, D	2002	43	2331	Tetrahedron Lett	HCAPLUS
Lee, A	2001	3	3707	Org Lett	HCAPLUS
Lee, Y	2000	2	303	Org Lett	HCAPLUS
Liu, G	1997	119	9913	J Am Chem Soc	HCAPLUS
Liu, G	1999	64	1278	J Org Chem	HCAPLUS
Owens, T	2001	123	1539	J Am Chem Soc	HCAPLUS
Pflum, D	2002	43	923	Tetrahedron Lett	HCAPLUS
Plobeck, N	2002	13	303	Tetrahedron:Asymmetr	HCAPLUS
Prakash, G	2001	40	589	Angew Chem, Int Ed	HCAPLUS
Prakash, G	2001	3	2847	Org Lett	HCAPLUS
Senanayake, C	2001			WO 0151453	HCAPLUS
Senanayake, C	1999	2	590	Curr Opin Drug Disco	HCAPLUS
Tang, T	2001	66	8772	J Org Chem	HCAPLUS
Zhou, P	2000	2	249	Advances in Sulfur C	

L64 ANSWER 6 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:449632 HCAPLUS
DN 137:20209
TI Preparation of hydroxylated **sibutramine** analogs as neuronal monoamine uptake inhibitors
IN **Senanayake, Chrisantha H.**; **Rubin, Paul D.**; **Jerussi, Thomas P.**
PA **Sepracor** Inc., USA
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002046138	A2	20020613	WO 2001-US47433	20011204 <--
WO 2002046138	A3	20030123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002115727	A1	20020822	US 2001-998195	20011203	<--
AU 2002039572	A5	20020618	AU 2002-39572	20011204	<--
EP 1353896	A2	20031022	EP 2001-987345	20011204	<--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2000-250524P	P	20001204	<--	
US 2000-257052P	P	20001222	<--	
WO 2001-US47433	W	20011204		

OS MARPAT 137:20209

GI



II

AB Title compds. 4-ClC6H4CR2CH(NR1R2)CHR4CHMeCH2R3 (I; R2 = CH2CHR5CH2; R1,R2 = H or alkyl; ≥1 of R3-R5 = OH or alkoxy and the others = H, oh alkoxy) were prepared Thus, 1-(4-chlorophenyl)cyclobutanecarboxaldehyde was condensed with (R)-Me2CSONH2 and the product subjected to asym. addition by chiral O-protected LiCH2CHMeCH2OH to give, e.g., title compound II. Data for biol. activity of I were given.

IT **435343-58-1P 435343-59-2P 435343-60-5P**
435343-61-6P 435343-63-8P 435343-64-9P
435343-65-0P 435343-66-1P 435343-67-2P
435343-68-3P 435343-69-4P 435343-70-7P
435343-71-8P 435343-72-9P 435343-73-0P
435343-74-1P 435343-76-3P 435343-78-5P
435343-80-9P 435343-82-1P 435343-83-2P
435343-84-3P 435343-86-5P 435343-88-7P
435343-89-8P 435343-93-4P 435343-94-5P
435343-95-6P 435343-96-7P 435343-97-8P
435343-98-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxylated **sibutramine** analogs as neuronal monoamine uptake inhibitors)

L64 ANSWER 7 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:425451 HCAPLUS
DN 137:5981
TI Preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors.
IN **Senanayake, Chrisantha Hugh**; Fang, Qun Kevin; Han, Zhengxu; Krishnamurthy, Dhileepkumar
PA **Sepracor** Inc., USA
SO U.S., 22 pp., Cont.-in-part of U. S. Ser. No. 372,158.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI US 6399826	B1	20020604	US 2000-480889	20000111	<--

US 6331571 B1 20011218 US 1999-372158 19990811 <--
WO 2001051453 A1 20010719 WO 2001-US762 20010110 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1246789 A1 20021009 EP 2001-901941 20010110 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2003519675 T2 20030624 JP 2001-551835 20010110 <--
US 2002183281 A1 20021205 US 2002-160033 20020604 <--
US 2003195261 A1 20031016 US 2003-395298 20030325 <--
PRAI US 1999-372158 A2 19990811 <--
US 1998-97665P P 19980824 <--
US 1998-99306P P 19980902 <--
US 2000-480889 A 20000111 <--
WO 2001-US762 W 20010110
US 2001-806 A3 20011204
OS CASREACT 137:5981; MARPAT 137:5981
GI



I

AB Several title compds. were prepared Thus, (-)-**sibutramine** was heated with di-Et azodicarboxylate in PhMe at 50° for 12 h to give (-)-desmethylsibutramine. (+)-Desmethylsibutramine inhibited norepinephrine uptake at human recombinant NE sites with IC50 = 4 nM. Intermediates (I; R = alkyl) are claimed.

IT **259731-39-0P**, (S)-Desmethylsibutramine hydrochloride
259731-40-3P, (R)-Desmethylsibutramine hydrochloride
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors)

IT **84467-54-9P**, (±)-Didesmethylsibutramine **168835-59-4P**, (±)-Desmethylsibutramine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors)

IT **84467-94-7P**, Desmethylsibutramine hydrochloride
229639-55-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors)

IT **229639-56-9**, (+)-Didesmethylsibutramine **229639-57-0**,

(-)-Didesmethylsibutramine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors)

IT **84485-00-7P, Sibutramine** hydrochloride
106650-56-0P, Sibutramine 153341-22-1P, (-)-Sibutramine 153341-23-2P 259729-90-3P 259729-91-4P 259729-92-5P 259729-93-6P 259729-95-8P 391905-99-0P 433305-28-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of **sibutramine** metabolites as norepinephrine and serotonin reuptake inhibitors)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abou-Gharbia	1991			US 4988814 A	HCAPLUS
Anon	1981			EP 0035597	HCAPLUS
Anon	1982			GB 2098602 A	HCAPLUS
Anon	1982			DE 3212682 A1	HCAPLUS
Anon	1988			WO 8806444	HCAPLUS
Anon	1990			WO 9006110	HCAPLUS
Anon	1994			WO 9400047	HCAPLUS
Anon	1994			WO 9400114	HCAPLUS
Anon	1994			WO 9428902	HCAPLUS
Anon	1995			WO 9520949	HCAPLUS
Anon	1995			WO 9521615	HCAPLUS
Anon	1997			EP 0781561 A1	HCAPLUS
Anon	1997			WO 9703675	HCAPLUS
Anon	1997			WO 9720810	HCAPLUS
Anon	1998			WO 9806722	HCAPLUS
Anon	1998			WO 9811884	HCAPLUS
Anon	1998			WO 9813033	HCAPLUS
Anon	1998			WO 9813034	HCAPLUS
Anon	1999			WO 9933450	HCAPLUS
Anon	1997			Diagnostic and Stati	
Anon	1981			Diagnostic and Stati	
Anon	1985			Introduction to Phar	
Anon	1993	36	2540	J Med Chem	
Anon	1999		2908	Physicain's Desk Ref	
Anon	1998		2520	Physician's Desk Ref	
Anon	1998		2958	Physician's Desk Ref	
Anon	1999		1054	Physician's Desk Ref	
Anon	1999		1332	Physician's Desk Ref	
Anon	1999		1369	Physician's Desk Ref	
Anon	1999		1432	Physician's Desk Ref	
Anon	1999		1494	Physician's Desk Ref	
Anon	1999		1641	Physician's Desk Ref	
Anon	1999		2004	Physician's Desk Ref	
Anon	1999		2075	Physician's Desk Ref	
Anon	1999		2190	Physician's Desk Ref	
Anon	1999		2367	Physician's Desk Ref	
Anon	1999		2396	Physician's Desk Ref	
Anon	1999		2490	Physician's Desk Ref	
Anon	1999		2516	Physician's Desk Ref	
Anon	1999		2688	Physician's Desk Ref	
Anon	1999		2701	Physician's Desk Ref	
Anon	1999		2720	Physician's Desk Ref	
Anon	1999		2735	Physician's Desk Ref	
Anon	1999		2886	Physician's Desk Ref	
Anon	1999		3092	Physician's Desk Ref	

Anon	1999		3101	Physician's Desk Ref	
Anon	1999		3224	Physician's Desk Ref	
Anon	1999		3267	Physician's Desk Ref	
Anon	1999		3307	Physician's Desk Ref	
Anon	1999		3383	Physician's Desk Ref	
Anon	1999		473	Physician's Desk Ref	
Anon	1999		475	Physician's Desk Ref	
Anon	1999		764	Physician's Desk Ref	
Anon	1999		823	Physician's Desk Ref	
Anon	1999		978	Physician's Desk Ref	
Anon	1980			Remington's Pharmace	
Anon	1990			Remington's Pharmace	
Anon	1999			The Merck Manual of	
Anon				U S Pharmacopia (USP)	
Applezweig	1970			US 3536809 A	HCAPLUS
Baldessarini	1986	39	1765	Life Science	HCAPLUS
Bell	1993			US 5250534 A	HCAPLUS
Bell	1998			US 5719283 A	HCAPLUS
Buckett	1988	13	736	Drugs of the Future	
Buckett	1988	2	167	New Concepts in Depr	
Buckett	1988	12	575	Prog Neuro-psychopha	HCAPLUS
Butler, D	1971	36	1308	J Org Chem	HCAPLUS
Cananne, P	1980	21	155	Tetrahedron Lett	
Carstensen, J	1995		379	Drug Stability:Princ	
Castello, R	1962	51	106	Pharm Sci	
Cheetham, S	1993	32	737	Neuropharmacology	HCAPLUS
Cliffe	1993	36	1509	Med Chem	HCAPLUS
Diherty	2000			US 6127363 A	HCAPLUS
Dreshfield	1996	21	557	Neurochem Res	HCAPLUS
Eliel, E	1962			Sterochemistry of Ca	
Eswara	1998			US 5780051 A	HCAPLUS
Evans	1989	262	2551	J A M A	MEDLINE
Fuentes, J	1976				HCAPLUS
Gennaro	1995		1625	Remingtons:The Pract	
Goodman & Gilman	1996		362	The Pharmacological	
Gray, A	1998	124	669	BR J Pharmacol	HCAPLUS
Heal, D	1998	125	301	BR J Pharmacol	HCAPLUS
Hillver	1990	33	1541	J Med Chem	HCAPLUS
Jacques	1981			Enantiomers, Racemat	
Jamali	1989	78	695	Journal of Pharmaceu	HCAPLUS
Janssen	1964			US 3155669 A	HCAPLUS
Janssen	1964			US 3155670 A	HCAPLUS
Jeffery	1985			US 4522828 A	HCAPLUS
Jeffery	1988			US 4746680 A	HCAPLUS
Jeffery	1989			US 4806570 A	HCAPLUS
Jeffery	1989			US 4814352 A	HCAPLUS
Jeffery	1990			US 4929629 A	HCAPLUS
Jeffery	1991			US 5068440 A	HCAPLUS
Jeffery, J	1996		2583	J Chem Soc Perkin Tr	HCAPLUS
King	1988	26	607	Br J Clin Pharm	HCAPLUS
Kula	1984	34	2567	Life Sciences	HCAPLUS
Le Grazie	1991			US 5059595 A	HCAPLUS
Lewis	1998			US 5733566 A	
Luscombe, G	1989	28	129	Neuropharmacology	HCAPLUS
Malen	1976			US 3960891 A	HCAPLUS
Marshall	1991			US 5073543 A	HCAPLUS
McClelland	1992			US 5120548 A	HCAPLUS
Middlemiss	1992	16	75	Neurosci and Biobehv	HCAPLUS
Mohr	1997			US 5591767 A	HCAPLUS
Moreau	1992	29	901	Brain Res Bull	HCAPLUS
Nakada, Y	1997	38	857	Tetrahadron Lett	HCAPLUS
Oshlack	1997			US 5639476 A	HCAPLUS
Rees	1989			US 4816488 A	HCAPLUS

Rees	1989			US 4871774 A	HCAPLUS
Scheinbaum	1995			US 5436272 A	HCAPLUS
Shinoda	1997			US 5674553 A	
Sparks	1994			US 5354556 A	HCAPLUS
Stock, M	1997	21	S25	Int'l J Obesity	
Svec	1998			US 5795880 A	HCAPLUS
Theeuwes	1974			US 3845770 A	HCAPLUS
Theeuwes	1975			US 3916899 A	HCAPLUS
Theeuwes	1977			US 4008719 A	
Toya	1985			US 4552828 A	HCAPLUS
Troxler	1969			US 3471515 A	HCAPLUS
Ukai	1990			US 4939175 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS
Wade	1994		257	Handbook of Pharmace	
Wilen	1977	33	2725	Tetrahedron	HCAPLUS
Wilen, S	1972			Tables of Resolving	
Wong	1996			US 5552429 A	HCAPLUS
Young	1992			US 5104899 A	HCAPLUS
Zaffaroni	1971			US 3598123 A	HCAPLUS

L64 ANSWER 8 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:314938 HCAPLUS
DN 136:340674
TI Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists, for treatment of diseases and disorders, for increasing lean meat content in animals, and for use in combination with other antiobesity agents
IN Day, Robert Francis; Lafontaine, Jennifer Anne
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002032897	A1	20020425	WO 2001-IB1847	20011004	<--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	AU 2001092161	A5	20020429	AU 2001-92161	20011004	<--
	BR 2001014836	A	20030701	BR 2001-14836	20011004	<--
	EP 1326861	A1	20030716	EP 2001-972390	20011004	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 2002052392	A1	20020502	US 2001-981551	20011017	<--
	US 6566377	B2	20030520			
	US 2003203913	A1	20031030	US 2003-379976	20030305	<--
	NO 2003001573	A	20030416	NO 2003-1573	20030408	<--
PRAI	US 2000-242274P	P	20001020	<--		
	WO 2001-IB1847	W	20011004			
	US 2001-981551	A3	20011017			

OS MARPAT 136:340674
GI



I



II

AB The invention provides β3-adrenergic receptor agonists (no data) of structural formula I [wherein Ar = pyridyl, oxazolyl, thiazolyl, or Ph; R = H, OH, oxo, halo, CF3, alkyl, alkoxy, cycloalkyl, NH2 or certain derivs., sulfonyl groups; R1 = H, alkyl, halo, alkoxy, OH; R2, R3, R4 = H, alkyl; R5 = 5- or 6-membered heterocycle with 1-4 N/O/S atoms; R6, R7 = H, halo, cyano, oxo, acyl, CO2H or derivs., OH, NH2 or derivs., (un)substituted alkyl, etc.; R8 = H, alkyl, halo; X = direct bond or O; Y = direct bond, alkylene, OCH2, CH2O, or O; with provisos], as well as the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compds., stereoisomers, and prodrugs. The invention further provides intermediates useful in the preparation of I, as well as therapeutic combinations of I and/or their stereoisomers/prodrugs/salts, with (other) anti-obesity agents. Over 60 invention compds. and 40 intermediates are named individually in claims. Exemplary prepns. of many intermediates and several invention compds. are given. For instance, reaction of (R)-2-chloro-5-oxiranylpyridine with 2-[4-(4-phenylthiazol-2-yl)phenoxy]ethylamine (preparation given) in EtOH at 80° gave 50% title compound (R)-II.

IT **106650-56-0, Sibutramine**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration with; preparation of α-arylethanolamines as β3-adrenergic receptor agonists, useful as drugs and agents for increasing lean meat content in animals)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ainsworth, A	1992			US 5153210 A	HCAPLUS
Beecham Group Plc	1988			EP 0295828 A	HCAPLUS
Dow, R	1999			US 5977124 A	HCAPLUS
Glaxo Group Limited	1999			WO 9965877 A	HCAPLUS
Hauel, N	1992			US 5135932 A	HCAPLUS
Pfizer Inc	1999			WO 9945006 A	HCAPLUS
Sankyo Company Limited	1993			EP 0543662 A	HCAPLUS
Schering Aktiengesellsc	1990			WO 9000548 A	HCAPLUS
Shuto, A	1997			US 5684022 A	HCAPLUS

L64 ANSWER 9 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:231253 HCAPLUS
DN 137:262796

TI First practical synthesis of enantiomerically pure (R)- and (S)-desmethylsibutramine (DMS) and unambiguous determination of their absolute configuration by single-crystal X-ray analysis
AU Han, Zhengxu; Krishnamurthy, Dhileepkumar; Pflum, Derek; Fang, Qun K.; Butler, Hal; Cameron, T. Stanley; Wald, Stephen A.; **Senanayake, Chris H.**
CS Chemical Process Research and Development, **Sepracor** Inc., Marlborough, MA, 01752, USA
SO Tetrahedron: Asymmetry (2002), 13(2), 107-109
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
AB A practical synthesis of enantiomerically pure (R)-desmethylsibutramine [(R)-DMS] and (S)-desmethylsibutramine [(S)-DMS] is outlined along with an improved synthesis of racemic desmethylsibutramine. This route was used for kilo-scale production of enantiomerically pure (R)- and (S)-DMS. Racemic desmethylsibutramine was resolved with either (R)- or (S)-mandelic acid, and the absolute stereochem. of DMS was determined by single X-ray crystallog. of its mandelate salt.
IT **259729-91-4P**
RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and resolution of desmethylsibutramine by addition of sec-butylmagnesium chloride to (chlorophenyl)cyclobutylcarbonitrile and subsequent resolution with mandelic acid)
IT **259731-39-0P 259731-40-3P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation and resolution of desmethylsibutramine by addition of sec-butylmagnesium chloride to (chlorophenyl)cyclobutylcarbonitrile and subsequent resolution with mandelic acid)
IT **259729-90-3P**
RL: IMF (Industrial manufacture); PRP (Properties); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, crystal structure and resolution of desmethylsibutramine by addition of sec-butylmagnesium chloride to (chlorophenyl)cyclobutylcarbonitrile and subsequent resolution with mandelic acid)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Barkers, J	1997			WO 9720810	HCAPLUS
Buckett, W	1988	12	575	Prog Neuropsychophar	HCAPLUS
Butler, D	1971	36	1308	J Org Chem	HCAPLUS
Case, F	1934	56	715	J Am Chem Soc	HCAPLUS
Fang, Q	1999	10	4477	Tetrahedron: Asymmet	HCAPLUS
Jeffery, J	1996		2583	J Chem Soc, Perkin T	HCAPLUS
Reddy, G	1999	3	488	Org Process Res Deve	HCAPLUS
Young, J				WO 9400114	HCAPLUS
Young, J				WO 940047	

L64 ANSWER 10 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:197459 HCAPLUS
DN 137:169260
TI First asymmetric synthesis of (R)-desmethylsibutramine
AU Krishnamurthy, Dhileepkumar; Han, Zhengxu; Wald, Stephen A.; **Senanayake, Chris H.**
CS **Sepracor** Inc., Chemical Process Research and Development,

Marlborough, MA, 01752, USA
SO Tetrahedron Letters (2002), 43(13), 2331-2333
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 137:169260
AB A catalytic enantioselective addition of iso-Bu lithium to N-[[1-(4-chlorophenyl)cyclobutyl]methylene]methanamine is used as the key step in the asym. synthesis of (R)-desmethylsibutramine [i.e., (αR)-1-(4-chlorophenyl)-α-(2-methylpropyl)cyclobutanemethanamine], a single enantiomer version of a pharmacol. active metabolite of anti-obesity drug **sibutramine** (Meridia).
IT **229639-56-9P**, (R)-Desmethylsibutramine
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of (R)-desmethylsibutramine)
IT **154752-44-0**, (R)-**Sibutramine**
RL: RCT (Reactant); RACT (Reactant or reagent)
(asym. synthesis of (R)-desmethylsibutramine)
IT **84467-54-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Buckett, W	1988	12	575	Prog Neuropsychophar	HCAPLUS
Caron, S	2000	122	712	J Am Chem Soc	HCAPLUS
Davies, I	1996		1753	Chem Commun	HCAPLUS
Denmark, S	1994	116	8797	J Am Chem Soc	HCAPLUS
Denmark, S	2000	65	5875	J Org Chem	HCAPLUS
Emling, B	1959	24	657	J Org Chem	HCAPLUS
Enders, D	1997	8	1895	Tetrahedron: Asymmet	HCAPLUS
Fang, Q	1999		4477	Tetrahedron: Asymmet	HCAPLUS
Ishimaru, K	1996	52	13137	Tetrahedron	HCAPLUS
Kobayashi, S	1999	99	1069	Chem Rev	HCAPLUS
Krishnamurthy, D	2001			Presented at the 222	
Porter, J	2001	123	10409	J Am Chem Soc	HCAPLUS
Senanayake, C	2001			WO 01/51453	HCAPLUS

L64 ANSWER 11 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:72805 HCAPLUS
DN 136:139829
TI Compositions comprising **sibutramine** metabolites in combination with phosphodiesterase inhibitors
IN **Jerussi, Thomas P.**; **Senanayake, Chrisantha H.**; Fang, Qun K.
PA USA
SO U.S. Pat. Appl. Publ., 24 pp., Cont.-in-part of U.S. Ser. No. 662,135.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002010198	A1	20020124	US 2001-770663	20010129 <--
US 6476078	B2	20021105		
US 6331571	B1	20011218	US 1999-372158	19990811 <--
US 6339106	B1	20020115	US 2000-662135	20000914 <--
WO 2002060424	A2	20020808	WO 2002-US2040	20020123
WO 2002060424	A3	20030206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003096792	A1	20030522	US 2002-278097	20021023	<--
	US 2003195261	A1	20031016	US 2003-395298	20030325	<--
PRAI	US 1999-372158	A2	19990811	<--		
	US 2000-662135	A2	20000914	<--		
	US 1998-97665P	P	19980824	<--		
	US 1998-99306P	P	19980902	<--		
	US 2001-770663	A	20010129			
	US 2001-806	A3	20011204			

AB Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compns. and dosage forms are also disclosed which comprise a racemic or optically pure **sibutramine** metabolite and an optional drug. **Sibutramine** free base was prepared by the reaction of chlorbenzylnitrile dibromopropane in the presence of NaH in DMSO, followed by the treatment of the resulting 1-(4-chlorophenyl)cyclobutanecarbonitrile with isobutylmagnesium bromide and finally treatment with HCHO. The fee base was resolved into the (R) and (S) isomers and converted into their metabolites. Hard gelatin capsules contained racemic or optically pure **sibutramine** metabolite 5.0, microcryst. cellulose 90.0, pregelatinized starch 100.3, croscarmellose sodium 7.0, and Mg stearate 0.2 mg.

IT **153341-22-1P**
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)
(compns. comprising **sibutramine** metabolites in combination with phosphodiesterase inhibitor)

IT **106650-56-0P, Sibutramine 154752-44-0P 168835-59-4P 229639-54-7P 229639-55-8P 229639-56-9P 229639-57-0P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(compns. comprising **sibutramine** metabolites in combination with phosphodiesterase inhibitor)

IT **84467-54-9P 84467-94-7P 84485-00-7P 153341-23-2P 259729-90-3P 259729-91-4P 259729-92-5P 259729-95-8P 259731-39-0P 259731-40-3P 389056-70-6P 389056-73-9P 389056-74-0P 391682-39-6P 391905-99-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(compns. comprising **sibutramine** metabolites in combination with phosphodiesterase inhibitor)

L64 ANSWER 12 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:51989 HCAPLUS

DN 136:96083
TI Methods of using and compositions comprising (+)-**sibutramine** optionally in combination with other pharmacologically active compounds
IN Young, James W.; **Jerussi, Thomas P.**
PA USA
SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U. S. Ser. No. 442,263.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002006964	A1	20020117	US 2001-770393	20010129 <--
	WO 2002060427	A2	20020808	WO 2002-US2038	20020123
	WO 2002060427	A3	20030213		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003078303	A1	20030424	US 2002-295871	20021118 <--
PRAI	US 1995-442263	A2	19950516 <--		
	US 2001-770393	A	20010129		

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (+)-**sibutramine**, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor.

IT **84485-00-7P, Sibutramine** hydrochloride
153341-23-2P, (-)-Sibutramine hydrochloride
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(therapeutic compns. comprising (+)-**sibutramine** and optionally in combination with other pharmacol. active compds.)

IT **154752-44-0P, (+)-Sibutramine**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(therapeutic compns. comprising (+)-**sibutramine** and optionally in combination with other pharmacol. active compds.)

IT **106650-56-0P, Sibutramine**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(therapeutic compns. comprising (+)-**sibutramine** and optionally in combination with other pharmacol. active compds.)

IT **84467-54-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(therapeutic compns. comprising (+)-**sibutramine** and optionally in combination with other pharmacol. active compds.)

L64 ANSWER 13 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:51988 HCAPLUS
DN 136:107551
TI Method of using and compositions comprising (-) **sibutramine** optionally in combination with other pharmacologically active compounds
IN Young, James W.; **Jerussi, Thomas P.**
PA USA
SO U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 721,669.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002006963	A1	20020117	US 2001-770665	20010129 <--
	WO 2002060428	A2	20020808	WO 2002-US2039	20020123
	WO 2002060428	A3	20021219		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 1992-903040 B1 19920623 <--
US 1995-461608 B1 19950605 <--
US 2000-721669 A2 20001127 <--
US 2001-770665 A 20010129

AB This invention encompasses methods for the treatment and prevention of disorders that include, but are not limited to, eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. The invention further encompasses pharmaceutical compns. and dosage forms which comprise optically pure (-) **sibutramine**, optionally in combination with a phosphodiesterase inhibitor or a lipase inhibitor. A solution of 21.7 g L-dibenzyltartaric acid ("L-DBTA") in Et acetate was added to a solution of 12.3 g racemic **sibutramine** in Et acetate and the reaction mixture was heated to reflux and cooled to room temperature The white precipitate was collected and the solid was then suspended in Et acetate and heated at reflux for 30 min. The solid was collected and further crystallized in iso-Pr alc. to give 11.3 g of (-)-**sibutramine** L-DBTA (yield 76%). Free base was obtained by treatment of (-)-**sibutramine** L-DBTA with saturated aqueous NaHCO3 and extracted with chloroform. A pharmacol. study was conducted to determine the relative potency, comparative efficacy, binding affinity, and toxicity of the enantiomers and racemic mixture of **sibutramine**. A capsule contained (-) **sibutramine** 10.0, lactose 70.0, corn starch 19.5, and magnesium stearate 0.05 mg.

IT **84485-00-7P**, **Sibutramine** hydrochloride
106650-56-0P, **Sibutramine**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(method of using and compns. comprising (-) **sibutramine**

optionally in combination with other pharmacol. active compds.)

IT **84467-54-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(method of using and compns. comprising (-) **sibutramine** optionally in combination with other pharmacol. active compds.)

L64 ANSWER 14 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:39607 HCAPLUS
DN 136:96093
TI Methods and compositions using a **sibutramine** metabolite or other dopamine uptake inhibitors for the treatment and prevention of sexual dysfunction
IN **Jerussi, Thomas P.**; **Senanayake, Chrisantha H.**; Fang, Qun K.
PA **Sepracor**, Inc., USA
SO U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 372,158.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6339106	B1	20020115	US 2000-662135	20000914 <--
	US 6331571	B1	20011218	US 1999-372158	19990811 <--
	US 2002010198	A1	20020124	US 2001-770663	20010129 <--
	US 6476078	B2	20021105		
	WO 2002022114	A2	20020321	WO 2001-US28598	20010913 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001089062	A5	20020326	AU 2001-89062	20010913 <--
	EP 1320360	A1	20030625	EP 2001-968848	20010913 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003096792	A1	20030522	US 2002-278097	20021023 <--
	US 2003195261	A1	20031016	US 2003-395298	20030325 <--
PRAI	US 1999-372158	A2	19990811 <--		
	US 1998-97665P	P	19980824 <--		
	US 1998-99306P	P	19980902 <--		
	US 2000-662135	A2	20000914 <--		
	US 2001-770663	A3	20010129		
	WO 2001-US28598	W	20010913		
	US 2001-806	A3	20011204		

AB Methods are disclosed for the treatment and prevention of sexual dysfunction. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an addnl. pharmacol. active compound Pharmaceutical compns. and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an addnl. pharmacol. active compound Preferred dopamine reuptake inhibitors are racemic or optically pure **sibutramine** metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred addnl. pharmacol. active compds. include drugs that affect the central nervous system, such as 5-HT3 antagonists. Preparation of **sibutramine** metabolites is described.

IT **153341-22-1P**, **(-)-Sibutramine**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); RCT

(Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **154752-44-0P**, (+)-**Sibutramine**
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **84467-54-9P 168835-59-4P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **229639-54-7 229639-55-8 229639-56-9 229639-57-0**
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **106650-56-0 168835-59-4D**, clathrates **229639-54-7D**, clathrates **229639-55-8D**, clathrates **229639-56-9D**, clathrates **229639-57-0D**, clathrates
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **389056-70-6P**
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **153341-23-2P**, (-)-**Sibutramine** hydrochloride
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **259729-95-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **84467-94-7P 259729-90-3P 259729-91-4P 259729-93-6P 389056-73-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

IT **259731-39-0P 259731-40-3P 389056-74-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(**sibutramine** metabolite or other dopamine uptake inhibitors for treatment and prevention of sexual dysfunction)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Abou-Gharbia	1991			US 4988814 A	HCAPLUS
American Psychiatric As	1981			Diagnostic and Stati	
American Psychiatric As	1997			Diagnostic and Stati	
Anon	1981			EP 0035597	HCAPLUS
Anon	1982			GB 2098602 A	HCAPLUS

Anon	1982			DE 3212682 A1	HCAPLUS
Anon	1988			WO 8806444	HCAPLUS
Anon	1990			WO 9006110	HCAPLUS
Anon	1994			WO 9400047	HCAPLUS
Anon	1994			WO 9400114	HCAPLUS
Anon	1994			WO 9428902	HCAPLUS
Anon	1995			WO 9520949	HCAPLUS
Anon	1995			WO 9521615	HCAPLUS
Anon	1997			EP 0781561 A1	HCAPLUS
Anon	1997			WO 9703675	HCAPLUS
Anon	1997			WO 9720810	HCAPLUS
Anon	1998			WO 9806722	HCAPLUS
Anon	1998			WO 9811884	HCAPLUS
Anon	1998			WO 9813033	HCAPLUS
Anon	1998			WO 9813034	HCAPLUS
Anon	1999			WO 9933450	HCAPLUS
Anon	1993	36	2540	J Med Chem	
Anon	1998		2520	Physician's Desk Ref	
Anon	1998		2958	Physician's Desk Ref	
Anon	1999		1054	Physician's Desk Ref	
Anon	1999		1332	Physician's Desk Ref	
Anon	1999		1369	Physician's Desk Ref	
Anon	1999		1432	Physician's Desk Ref	
Anon	1999		1494	Physician's Desk Ref	
Anon	1999		1641	Physician's Desk Ref	
Anon	1999		2004	Physician's Desk Ref	
Anon	1999		2075	Physician's Desk Ref	
Anon	1999		2190	Physician's Desk Ref	
Anon	1999		2367	Physician's Desk Ref	
Anon	1999		2396	Physician's Desk Ref	
Anon	1999		2490	Physician's Desk Ref	
Anon	1999		2516	Physician's Desk Ref	
Anon	1999		2688	Physician's Desk Ref	
Anon	1999		2701	Physician's Desk Ref	
Anon	1999		2720	Physician's Desk Ref	
Anon	1999		2735	Physician's Desk Ref	
Anon	1999		2886	Physician's Desk Ref	
Anon	1999		2908	Physician's Desk Ref	
Anon	1999		3092	Physician's Desk Ref	
Anon	1999		3101	Physician's Desk Ref	
Anon	1999		3224	Physician's Desk Ref	
Anon	1999		3267	Physician's Desk Ref	
Anon	1999		3307	Physician's Desk Ref	
Anon	1999		3383	Physician's Desk Ref	
Anon	1999		473	Physician's Desk Ref	
Anon	1999		764	Physician's Desk Ref	
Anon	1999		978	Physician's Desk Ref	
Anon	1999		823	Physicina'ns Desk Re	
Anon	1980			Remington's Pharmace	
Anon	1990			Remington's Pharmace	
Applezweig	1970			US 3536809 A	HCAPLUS
Baldessarini	1986	39	1765	Life Sciences	HCAPLUS
Bell	1993			US 5250534 A	HCAPLUS
Bell	1998			US 5719283 A	HCAPLUS
Bucket	1988	12	575	Prog Neuro-Psychopha	
Buckett	1988	13	736	Drugs of the Future	
Buckett	1988	2	167	New Concepts in Depr	
Butler, D	1971	36	1308	J Org Chem	HCAPLUS
Cannonne, P	1980	21	155	Tetrahedron Lett	
Carstensen, J	1995		379	Drug Stability:Princ	
Castello, R	1962	51	106	Pharm Sci	
Cheetham, S	1993	32	737	Neuropharmacology	HCAPLUS
Cliffe	1993	36	1509	Med Chem	HCAPLUS

Doherty	2000			US 6127363 A	HCAPLUS
Dreshfield	1996	21	557	Neurochem Res	HCAPLUS
Eliel, E	1962			Stereochemistry of C	
Eswara	1998			US 5780051 A	HCAPLUS
Evans	1989	262	2551	J A M A	MEDLINE
Fuentes, J	1976				HCAPLUS
Gennaro	1995		1625	Remingtons:The Pract	
Goodman	1996		362	The Pharmacological	
Gray	1988	124	669	BR J Pharmacol	
Heal	1998	125	301	BR J Pharmacol	HCAPLUS
Hillyer	1990	33	1541	J Med Chem	
Jacques	1981			Enantiomers, Racemat	
Jamali	1989	78	695	Journal of Pharmaceu	HCAPLUS
Janssen	1964			US 3155669 A	HCAPLUS
Janssen	1964			US 3155670 A	HCAPLUS
Jeffery	1985			US 4522828 A	HCAPLUS
Jeffery	1988			US 4746680 A	HCAPLUS
Jeffery	1989			US 4806570 A	HCAPLUS
Jeffery	1989			US 4814352 A	HCAPLUS
Jeffery	1990			US 4929629 A	HCAPLUS
Jeffery	1991			US 5068440 A	HCAPLUS
Jeffrey	1996		2583	J Chem Soc Perkin Tr	
King	1989	26	607	Clinical Pharmac	
Kula	1984	34	2567	Life Sciences	HCAPLUS
Le Grazie	1991			US 5059595 A	HCAPLUS
Lea & Febiger	1985			Introduction to Phar	
Lewis	1998			US 5733566 A	
Luscombe	1989	28	129	Neuropharmacology	HCAPLUS
Malen	1976			US 3960891 A	HCAPLUS
Marshall	1991			US 5073543 A	HCAPLUS
McClelland	1992			US 5120548 A	HCAPLUS
Merck & Co Inc	1999			The Merck Manual of	
Middlemiss	1992	16	75	Neurosci and Biobehv	HCAPLUS
Mohr	1997			US 5591767 A	HCAPLUS
Moreau	1992	29	901	Brain Res Bull	HCAPLUS
Nakada	1997	38	857	Tetrahedron Lett	HCAPLUS
Oshlack	1997			US 5639476 A	HCAPLUS
Rees	1989			US 4816488 A	HCAPLUS
Rees	1989			US 4871774 A	HCAPLUS
Scheinbaum	1995			US 5436272 A	HCAPLUS
Shinoda	1997			US 5674553 A	
Sparks	1994			US 5354556 A	HCAPLUS
Stock, M	1997	21	S25	Int'l J Obesity	
Svec	1998			US 5795880 A	HCAPLUS
Theeuwes	1974			US 3845770 A	HCAPLUS
Theeuwes	1975			US 3916899 A	HCAPLUS
Theeuwes	1977			US 4008719 A	
Toya	1985			US 4552828 A	HCAPLUS
Troxler	1969			US 3471515 A	HCAPLUS
Ukai	1990			US 4939175 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS
Wade	1994		257	Handbook of Pharmace	
Wilen	1977	33	2725	Tetrahedron	HCAPLUS
Wilen, S	1972	268		Tables of Resolving	
Wong	1996			US 5552429 A	HCAPLUS
Young	1992			US 5104899 A	HCAPLUS
Zaffaroni	1971			US 3598123 A	HCAPLUS

L64 ANSWER 15 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:640598 HCAPLUS
TI Studies toward the practical synthesis of optically pure desmethylsibutramine
AU Krishnamurthy, Dhileepkumar; Han, Zhengxu; Pflum, Derek; Fang, Qun K.;

Grover, Paul; Butler, Hal; Kessler, Donnald W.; Wald, Stephen A.; **Senanayake, Chris**

CS Chemical Process Research and Development, **Sepracor** Inc, Marlborough, MA, 01752, USA

SO Abstracts of Papers, 222nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001 (2001), ORGN-235 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69BUZP

DT Conference; Meeting Abstract

LA English

AB Desmethylsibutramine (DMS) 1 is a pharmacol. active metabolite of **sibutramine** 2, a new class of compound for the treatment of obesity. In order to evaluate the effectiveness of DMS towards various indications, kilo quantities of both (R) and (S)-DMS in optically pure form are required. A practical second-generation synthesis of the optically pure (R)-DMS and (S)-DMS will be presented along with the improved synthesis for racemic desmethylsibutramine. This route was used for large-scale production of optically pure (R)- and (S)-DMS. Preliminary results from the catalytic asym. synthesis of DMS will also be presented.

L64 ANSWER 16 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:526047 HCAPLUS

DN 135:122299

TI Synthesis of racemic and optically pure desmethylsibutramine, didesmethylsibutramine, oral formulations comprised thereof and their use as dopamine reuptake inhibitors

IN **Senanayake, Chrisantha H.**; Fang, Qun K.; Han, Zhengxu; Krishnamurthy, Dhileepkumar

PA **Sepracor** Inc., USA

SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001051453	A1	20010719	WO 2001-US762	20010110 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6399826	B1	20020604	US 2000-480889	20000111 <--
	EP 1246789	A1	20021009	EP 2001-901941	20010110 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003519675	T2	20030624	JP 2001-551835	20010110 <--
PRAI	US 2000-480889	A	20000111 <--		
	US 1999-372158	A2	19990811 <--		
	WO 2001-US762	W	20010110		

OS MARPAT 135:122299

GI



I

AB Racemic and optically pure **sibutramine** metabolites, desmethyl- (I, X = Me) and didesmethylsibutramine I (X = H; II) were prepared Addition of i-butylmagnesium bromide to 1-(4-chlorophenyl)cyclobutanecarbonitrile followed by MeOH quench and treatment with NaBH4 produced II. II was converted to the N-formyl derivative and reduced to give I. Resolution with (R)-mandelic acid furnished (R)-I. **Sibutramine** isomers are inhibitors of norepinephrine (NE) and 5-HT uptake and bind to muscarinic receptors while metabolites I and II were found to have affinity for NE, 5-HT and negligible activity at muscarinic sites. At NE reuptake sites, (+)-I had IC50 = 4 nM (vs. (-)-I IC50 = 870 nM), and reuptake site binding selectivity for NE/5-HT = 12. A lactose free solid oral dosage hard gelatin capsule and tablet formulation was provided. Methods to treat neuropathic pain and diabetic peripheral neuropathy were claimed.

IT **84467-54-9P 84467-94-7P 84485-00-7P,**
Sibutramine hydrochloride **106650-56-0P,**
Sibutramine 153341-22-1P, (-)-**Sibutramine**
153341-23-2P, (-)-**Sibutramine** hydrochloride
154752-44-0P, (+)-**Sibutramine 154752-45-1P,**
(+)-**Sibutramine** hydrochloride **168835-59-4P**
229639-54-7P 229639-55-8P 229639-56-9P
229639-57-0P 259731-39-0P 259731-40-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis of racemic and optically pure desmethylsibutramine, didesmethylsibutramine, oral formulations comprised thereof and their use as dopamine reuptake inhibitors)

IT **259729-90-3P 259729-91-4P 259729-92-5P**
259729-93-6P 259729-95-8P 260402-77-5P
350701-71-2P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of racemic and optically pure desmethylsibutramine, didesmethylsibutramine, oral formulations comprised thereof and their use as dopamine reuptake inhibitors)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Boots Co Plc	1982			GB 2098602 A	HCAPLUS
Boots Co Plc	1986			EP 0191542 A	HCAPLUS
Emmelmann, G	2000			WO 0032182 A	
Fang, Q	1999	10	4477	TETRAHEDRON: ASYMMET	HCAPLUS
Sepracor Inc	2000			WO 0010551 A	HCAPLUS

L64 ANSWER 17 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:356206 HCAPLUS
DN 134:348292
TI Methods and pharmaceutical compositions containing Apo B secretion/microsomal triglyceride transfer protein inhibitors and anti-obesity agents for the treatment of obesity

IN Morgan, Bradley Paul; Swick, Andrew Gordon
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1099441	A2	20010516	EP 2000-309753	20001103 <--
	EP 1099441	A3	20021204		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000005318	A	20010807	BR 2000-5318	20001109 <--
	JP 2001139491	A2	20010522	JP 2000-344124	20001110 <--
PRAI	US 1999-164780P	P	19991110 <--		

OS MARPAT 134:348292
AB The invention provides methods and pharmaceutical compns. containing Apo B secretion/MTP inhibitors and anti-obesity agents for the treatment of obesity an animal, preferably a mammal including a human subject, a companion animal, or livestock, using an apo B secretion/MTP inhibitor and an anti-obesity agent. The invention further provides to a kit comprising an amount of an apolipoprotein B secretion/microsomal triglyceride transfer protein inhibitor and a pharmaceutically acceptable carrier, vehicle or diluent in a first unit dosage form; an amount of an anti-obesity agent and a pharmaceutically acceptable carrier, vehicle or diluent in a second unit dosage form; and a container.
IT **106650-56-0**, **Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo B secretion/MTP inhibitors-containing pharmaceutical compns. and anti-obesity agents for the treatment of obesity)

L64 ANSWER 18 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:356205 HCAPLUS
DN 134:361376
TI Use of apo B secretion/MTP inhibitors for reducing intestinal fat absorption
IN Chandler, Charles Edward; Hickman, Mary Anne; Lundy, Kristin Marie; Morgan, Bradley Paul
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1099439	A2	20010516	EP 2000-309721	20001103 <--
	EP 1099439	A3	20030326		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	ZA 2000006419	A	20020508	ZA 2000-6419	20001108 <--
	NZ 508059	A	20021126	NZ 2000-508059	20001109 <--
	JP 2001172180	A2	20010626	JP 2000-342892	20001110 <--
PRAI	US 1999-164547P	P	19991110 <--		

OS MARPAT 134:361376
GI



I



II

AB Microsomal triglyceride transfer protein apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (MTP) inhibitors are used for reducing intestinal fat absorption in animals and humans. Antiobesity agents may be included in the formulations. I and II reduced intestinal fat absorption in dogs by 49% and 26%, resp.

IT **106650-56-0, Sibutramine**
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo B secretion/MTP inhibitors for reducing intestinal fat absorption)

L64 ANSWER 19 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:356204 HCAPLUS
DN 134:361375
TI Use of apo B secretion/MTP inhibitors as antiobesity agents
IN Hickman, Mary Anne; Lundy, Kristin Marie; Morgan, Bradley Paul
PA Pfizer Products Inc., USA
SO Eur. Pat. Appl., 22 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	EP 1099438	A2	20010516	EP 2000-309705	20001103	<--
	EP 1099438	A3	20030319			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	ZA 2000006417	A	20020508	ZA 2000-6417	20001108	<--
	NZ 508061	A	20020426	NZ 2000-508061	20001109	<--
	JP 2001181209	A2	20010703	JP 2000-344128	20001110	<--
PRAI	US 1999-164513P	P	19991110	<--		

OS MARPAT 134:361375
GI



I

AB The invention relates to methods and pharmaceutical compns. useful in reducing food intake in an animal, preferably a mammal including a human subject or a companion animal, using a microsomal triglyceride transfer protein apolipoprotein B (apo B) secretion/microsomal triglyceride transfer protein (MTP) inhibitor. Antiobesity agents may be included in the formulations. I and II reduced food intake in dogs by 58% and 30%, resp.

IT **106650-56-0, Sibutramine**
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apo B secretion/MTP inhibitors as antiobesity agents)

L64 ANSWER 20 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:895223 HCAPLUS
DN 135:40851
TI Effects of chronic administration of **sibutramine** on body weight, food intake and motor activity in neonatally monosodium glutamate-treated obese female rats: Relationship of antiobesity effect with monoamines
AU Nakagawa, Terutake; Ukai, Kiyoharu; Ohyama, Tadashi; Gomita, Yutaka; Okamura, Hitoshi
CS Central Research Institute, Kaken Pharmaceutical Co. Ltd., Kyoto, 607-8042, Japan
SO Experimental Animals (**2000**), 49(4), 239-249
CODEN: JIDOAA; ISSN: 1341-1357
PB Japanese Association for Laboratory Animal Science
DT Journal
LA English
AB When the hypothalamic ventromedial nucleus and arcuate nucleus were destroyed in rats by treatment with monosodium glutamate in the neonatal stage, increase in the Lee index (body weight 1/3/body length) and in retroperitoneal fat as well as decreases in spontaneous motor activity, food consumption and growth hormone secretion function associated with hypothalamic low body length obesity (monosodium glutamate-treated obesity; MSG-OB) were observed as these rats grew. Treatment with **sibutramine** at 3 and 10 mg/kg p.o. once a day continuously for 14 days improved these parameters, and the degree of improvement was dose related. The plasma lipid values in MSG-OB rats, which were the same as those in normal rats, were decreased by consecutive administration of **sibutramine**. Levels of hypothalamic monoamines (MAs) such as norepinephrine, 5-HT (serotonin) and dopamine and their metabolites DOPAC, HVA and 5-HIAA were decreased in MSG-OB rats, and further decrease in them, though slight, was observed with consecutive daily administration of **sibutramine**, probably as a result of the feedback attributable to an increase in MA in synapses caused by inhibition of MA uptake by **sibutramine**. These results suggest that **sibutramine** can activate the MA nervous system by MA uptake inhibition in regions of the brain such as the lateral hypothalamic area and the paraventricular nucleus, which control food intake and sympathetic nerve activity, and the

nigrostriatal area related to the extrapyramidal motor system, and thereby exhibit anti-obesity effects in the MSG-OB rat.

IT **106650-56-0, Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hypothalamic monoamines and effects of chronic **sibutramine** on body weight, food intake and motor activity in monosodium glutamate-treated obese female rats)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Baptista, T	1997	30	43	Pharmacopsychiatry	HCAPLUS
Bray, G	1985	14	505	Brain Res Bull	HCAPLUS
Bray, G	1996	4	263	Obesity Res	HCAPLUS
Bray, G	1998	53	95	Recent Prog Horm Res	HCAPLUS
Buckett, W	1988	12	575	Prog Neuro-Psychopha	HCAPLUS
Connoley, I	1999	126	1487	Br J Pharmacol	HCAPLUS
Cox, C	1967		105	Statsistics in endoc	
Currie, P	1997	8	3759	Neuroreport	HCAPLUS
Day, C	1998	22	619	Int J Obes Relat Met	HCAPLUS
Dulloo, A	1991	40	113	Metabolism	HCAPLUS
Edwards, S	1994	47	865	Pharmacol Biochem Be	HCAPLUS
Egawa, M	1991	260	328	Am J Physiol	
Fletcher, P	1989	32	907	Pharmacol Biochem Be	HCAPLUS
Ganong, W	1999		221	Review of Medical Ph	
Grignaschi, G	1999	127	1190	Br J Pharmacol	HCAPLUS
Gundlah, C	1997	283	581	J Pharmacol Exp Ther	HCAPLUS
Heal, D	1991	103	251	Psychopharmacology	HCAPLUS
Heal, D	1992	107	303	Psychopharmacology	HCAPLUS
Jackson, H	1997	121	1613	Br J Pharmacol	HCAPLUS
Jackson, H	1997	121	1758	Br J Pharmacol	HCAPLUS
Johnston, C	1984	13	643	Brain Res Bull	HCAPLUS
Karoum, F	1984	100	137	Eur J Pharmacol	HCAPLUS
Leibowitz, S	1979	172	101	Brain Res	MEDLINE
Leibowitz, S	1988	21	905	Brain Res Bull	HCAPLUS
Leibowitz, S	1978	8	163	Pharmacol Biochem Be	MEDLINE
Martin, K	1995	51	565	Pharmacol Biochem Be	HCAPLUS
Masuda, C	1989	9	155	Jpn J Psychopharmaco	
Mousseau, D	1989	75	73	J Neural Transm	MEDLINE
Mousseau, D	1989	75	73	J Neural Transm	MEDLINE
Nakagawa, T	1994		369	A recent advance in	
Nakagawa, T	1998	44	162	Exp Anim	
Nakagawa, T	1996	59	705	Life Sci	HCAPLUS
Nakagawa, T	1997	58	829	Pharmacol Biochem Be	HCAPLUS
Nemeroff, C	1977	101	614	Endocrinology	
Nemeroff, C	1977	2	179	Psychoneuroendocrino	HCAPLUS
Oida, K	1984	8	385	Int J Obes	HCAPLUS
Paez, X	1993	46	933	Pharmacol Biochem Be	HCAPLUS
Sakaguchi, T	1989	492	271	Brain Res	HCAPLUS
Stricker-Konggrad, A	1995	19	398	Int J Obes	
Stricker-Konggrad, A	1995	19	399	Int J Obes	
Weiser, M	1997	37	453	J Clin Pharmacol	HCAPLUS
Weiss, G	1986	25	1223	Pharmacol Biochem Be	HCAPLUS
Williams, T	1984	311	1403	N Engl J Med	HCAPLUS
Wortley, K	1999	128	659	Br J Pharmacol	HCAPLUS
Yoshida, T	1990	36	123	J Nutr Sci Vitaminol	HCAPLUS
Zhang, W	1994	35	383	Brain Res Bull	HCAPLUS

L64 ANSWER 21 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688080 HCAPLUS
DN 133:232824

TI Treatment of cancers associated with weight gain with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000056323	A1	20000928	WO 2000-US7361	20000317	<--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA					
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	NZ 514012	A	20010928	NZ 2000-514012	20000317	<--
	EP 1171106	A1	20020116	EP 2000-915015	20000317	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 2000009161	A	20020122	BR 2000-9161	20000317	<--
	JP 2002539255	T2	20021119	JP 2000-606228	20000317	<--
	NO 2001004478	A	20011029	NO 2001-4478	20010914	<--
	ZA 2001007687	A	20021218	ZA 2001-7687	20010918	<--
	BG 105998	A	20020628	BG 2001-105998	20011010	<--
PRAI	US 1999-125250P	P	19990319	<--		
	WO 2000-US7361	W	20000317	<--		

OS MARPAT 133:232824
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating cancers associated with obesity, including colon cancer, breast cancer, endometrial cancer, and gallbladder cancer.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of obesity-associated cancer)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Jeffery	1991			US 5068440 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 22 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688079 HCAPLUS
DN 133:232843
TI Treatment to lower platelet adhesiveness with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056322	A1	20000928	WO 2000-US7255	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1178790	A1	20020213	EP 2000-918125	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6380260	B1	20020430	US 2000-528343	20000317 <--
	JP 2002539254	T2	20021119	JP 2000-606227	20000317 <--
PRAI	US 1999-125335P	P	19990319 <--		
	WO 2000-US7255	W	20000317 <--		

OS MARPAT 133:232843
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for decreasing platelet adhesiveness.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for decreasing platelet

adhesiveness)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 23 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688078 HCAPLUS
DN 133:232866
TI Treatment of hyperactivity disorders with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056321	A1	20000928	WO 2000-US7254	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6372798	B1	20020416	US 2000-528046	20000317 <--
PRAI	US 1999-125333P	P	19990319 <--		

OS MARPAT 133:232866
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating hyperactivity disorders, e.g. attention deficit hyperactivity disorder and hyperkinetic disorder. Use of these compds. for treating eating disorders is also disclosed.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of hyperactivity disorders)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 24 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688077 HCAPLUS
DN 133:232865
TI Treatment of menstrual function and infertility with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056320	A1	20000928	WO 2000-US7242	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6372797	B1	20020416	US 2000-527811	20000317 <--
PRAI	US 1999-125339P	P	19990319 <--		

OS MARPAT 133:232865
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating menstrual function and infertility.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of menstrual function and infertility)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Ukai	1990			US 4939175 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 25 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688076 HCAPLUS
DN 133:232842
TI Treatment of orthostatic hypotension with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000056319	A1	20000928	WO 2000-US7230	20000317 <--
W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6365632	B1	20020402	US 2000-527963	20000317 <--
PRAI US 1999-125606P	P	19990319 <--		

OS MARPAT 133:232842
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating orthostatic hypotension.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**, **Sibutramine** hydrochloride **106650-56-0 106650-56-0D**, enantiomers **125494-59-9**, **Sibutramine** hydrochloride monohydrate **153341-22-1 154752-44-0 168835-59-4 168835-59-4D**, enantiomers **229639-54-7 229639-55-8 229639-56-9 229639-57-0**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of orthostatic hypotension)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 26 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688075 HCAPLUS
DN 133:232864
TI Treatment of neuropathic pain or fibromyalgia with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000056318	A1	20000928	WO 2000-US7204	20000317 <--

W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-125113P P 19990319 <--
OS MARPAT 133:232864
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating fibromyalgia or neuropathic pain, e.g. pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of neuropathic pain and fibromyalgia)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 27 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688074 HCAPLUS

DN 133:232863
TI **Sibutramine** and N-demethyl derivatives thereof for aiding weight loss after pregnancy
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056317	A1	20000928	WO 2000-US7202	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	NZ 514015	A	20010928	NZ 2000-514015	20000317 <--
	EP 1162966	A1	20011219	EP 2000-921401	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009078	A	20011226	BR 2000-9078	20000317 <--
	JP 2002539253	T2	20021119	JP 2000-606222	20000317 <--
	NO 2001004474	A	20011114	NO 2001-4474	20010914 <--
	BG 105995	A	20020628	BG 2001-105995	20011010 <--
PRAI	US 1999-125149P	P	19990319 <--		
	WO 2000-US7202	W	20000317 <--		

OS MARPAT 133:232863
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for aiding weight loss after pregnancy.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for aiding weight loss after pregnancy)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Scheinbaum |1995 | | |US 5436272 A |HCAPLUS

L64 ANSWER 28 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688073 HCAPLUS
DN 133:232880
TI Treatment of gallstones with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056316	A1	20000928	WO 2000-US7199	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1165060	A1	20020102	EP 2000-919462	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539252	T2	20021119	JP 2000-606221	20000317 <--
PRAI	US 1999-125609P	P	19990319 <--		
	WO 2000-US7199	W	20000317 <--		

OS MARPAT 133:232880
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating gallstones, particularly gallstones associated with gall bladder disease related to obesity.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of gallstones)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Boots Pharmaceuticals I	1995			WO 9520949 A1	HCAPLUS
Ukai	1990			US 4939175	HCAPLUS

L64 ANSWER 29 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688072 HCAPLUS
DN 133:232862
TI Treatment of pain with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056315	A1	20000928	WO 2000-US7178	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6376553	B1	20020423	US 2000-528036	20000317 <--
PRAI	US 1999-125120P	P	19990319 <--		

OS MARPAT 133:232862
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating pain, e.g. low back pain.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biolcgical study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of pain)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Jeffery	1991			US 5068440 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 30 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688071 HCAPLUS
DN 133:232861
TI Treatment of sleep disorders with **sibutramine** and N-demethyl derivatives thereof
IN Cheetham, Sharon Crawford; Heal, David John; Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.; Safer, Anton
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056314	A1	20000928	WO 2000-US7177	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	NZ 514014	A	20010928	NZ 2000-514014	20000317 <--
	EP 1169029	A1	20020109	EP 2000-918094	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009080	A	20020213	BR 2000-9080	20000317 <--
	US 6365631	B1	20020402	US 2000-527814	20000317 <--
	JP 2003521469	T2	20030715	JP 2000-606219	20000317 <--
	NO 2001004475	A	20011114	NO 2001-4475	20010914 <--
	BG 106001	A	20020628	BG 2001-106001	20011010 <--
PRAI	US 1999-125185P	P	19990319 <--		
	WO 2000-US7177	W	20000317 <--		

OS MARPAT 133:232861
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating sleeping disorders, including sleep apnea and snoring.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of sleep disorders)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Jeffery	1991			US 5068440 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 31 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688070 HCAPLUS
DN 133:232860
TI **Sibutramine** and N-demethyl derivatives thereof for controlling weight gain associated with therapeutic drugs
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056313	A1	20000928	WO 2000-US7130	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	NZ 514009	A	20010928	NZ 2000-514009	20000317 <--
	EP 1162965	A1	20011219	EP 2000-916480	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009159	A	20011226	BR 2000-9159	20000317 <--
	US 6376552	B1	20020423	US 2000-527962	20000317 <--
	JP 2002539251	T2	20021119	JP 2000-606218	20000317 <--
	CZ 291864	B6	20030618	CZ 2001-3283	20000317 <--
	NO 2001004480	A	20011102	NO 2001-4480	20010914 <--
	ZA 2001007692	A	20021218	ZA 2001-7692	20010918 <--
	BG 105997	A	20020628	BG 2001-105997	20011010 <--
PRAI	US 1999-125340P	P	19990319 <--		
	WO 2000-US7130	W	20000317 <--		

OS MARPAT 133:232860
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating weight gain associated with drug therapy, including the use of tricyclic antidepressants, lithium, sulfonylureas, β-adrenergic blockers, certain steroid contraceptives, corticosteroids, insulin, cyproheptadine, sodium valproate, neuroleptics, phenothiazines, or piztifen.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**

, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for controlling weight gain associated with drug therapy)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Scheinbaum	1995			US 5436272 A	HCAPLUS
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 32 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688069 HCAPLUS
DN 133:232841
TI Treatment of pulmonary hypertension with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056312	A1	20000928	WO 2000-US7124	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1162964	A1	20011219	EP 2000-916474	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6403650	B1	20020611	US 2000-527815	20000317 <--
	JP 2002539250	T2	20021119	JP 2000-606217	20000317 <--
PRAI	US 1999-125604P	P	19990319 <--		
	WO 2000-US7124	W	20000317 <--		

OS MARPAT 133:232841
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating

pulmonary hypertension, particularly in patients who take certain anorectic medications.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of pulmonary hypertension)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 33 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688068 HCAPLUS
DN 133:232850
TI Treatment of metabolic disorders with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056311	A1	20000928	WO 2000-US7123	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6441046	B1	20020827	US 2000-528050	20000317 <--
PRAI	US 1999-125117P	P	19990319 <--		

OS MARPAT 133:232850
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating metabolic disorders, e.g. increased non-exercise activity thermogenesis or increased metabolic rate.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**

, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of metabolic disorders)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Scheinbaum	1995			US 5436272 A	HCAPLUS
Ukai	1990			US 4939175 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 34 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688067 HCAPLUS
DN 133:232859
TI Treatment of chronic fatigue syndrome with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056310	A1	20000928	WO 2000-US7122	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6376551	B1	20020423	US 2000-527812	20000317 <--
PRAI	US 1999-125114P	P	19990319 <--		

OS MARPAT 133:232859
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating chronic fatigue syndrome.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,

Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of chronic fatigue syndrome)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 35 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688066 HCAPLUS
DN 133:232879
TI Treatment of sexual dysfunction with **sibutramine** and N-demethyl derivatives thereof
IN Cheetham, Sharon Crawford; Heal, David John
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056309	A1	20000928	WO 2000-US7114	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6376554	B1	20020423	US 2000-528149	20000317 <--
PRAI	US 1999-125151P	P	19990319 <--		

OS MARPAT 133:232879
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating sexual dysfunction.
IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,

enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of sexual dysfunction)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 36 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688065 HCAPLUS
DN 133:232840
TI Treatment and prevention of cardiovascular disease with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056308	A1	20000928	WO 2000-US7113	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6433020	B1	20020813	US 2000-527959	20000317 <--
PRAI	US 1999-125115P	P	19990319 <--		

OS MARPAT 133:232840
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating cardiovascular disease, e.g. dyslipidemia or carotid intimal medial thickening.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of cardiovascular disease)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 37 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688064 HCAPLUS
DN 133:232844
TI Treatment of hiatal hernia and reflux esophagitis with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056307	A1	20000928	WO 2000-US7112	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	NZ 514013	A	20010928	NZ 2000-514013	20000317 <--
	EP 1169028	A1	20020109	EP 2000-918070	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000009160	A	20020129	BR 2000-9160	20000317 <--
	JP 2002539249	T2	20021119	JP 2000-606212	20000317 <--
	NO 2001004476	A	20011029	NO 2001-4476	20010914 <--
	BG 106000	A	20020628	BG 2001-106000	20011010 <--
PRAI	US 1999-125116P	P	19990319 <--		
	WO 2000-US7112	W	20000317 <--		

OS MARPAT 133:232844
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating hiatal hernias and reflux esophagitis.

IT **84467-54-9** **84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,

Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of hiatal hernia and reflux esophagitis)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ukai	1990			US 4939175 A	HCAPLUS

L64 ANSWER 38 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688063 HCAPLUS
DN 133:247281
TI Treatment of osteoarthritis or gout with **sibutramine** and N-demethyl derivatives thereof
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056306	A1	20000928	WO 2000-US7072	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	NZ 514016	A	20010928	NZ 2000-514016	20000317 <--
	EP 1169027	A1	20020109	EP 2000-918058	20000317 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002539248	T2	20021119	JP 2000-606211	20000317 <--
	BR 2000009081	A	20030305	BR 2000-9081	20000317 <--
	NO 2001004477	A	20011101	NO 2001-4477	20010914 <--
	BG 105999	A	20020628	BG 2001-105999	20011010 <--
PRAI	US 1999-125300P	P	19990319 <--		
	WO 2000-US7072	W	20000317 <--		

OS MARPAT 133:247281
GI



I

AB Compds. I (R1, R2 = H, Me) or a pharmaceutically acceptable salt thereof (e.g. N,N,-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine-HCl, optionally in the form of its monohydrate) are used for treating

osteoarthritis or gout.

IT **84467-54-9 84467-54-9D**, enantiomers **84485-00-7**
, **Sibutramine** hydrochloride **106650-56-0**
106650-56-0D, enantiomers **125494-59-9**,
Sibutramine hydrochloride monohydrate **153341-22-1**
154752-44-0 168835-59-4 168835-59-4D,
enantiomers **229639-54-7 229639-55-8**
229639-56-9 229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(**sibutramine** and N-demethyl derivs. for treatment of osteoarthritis and gout)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Jeffery	1991			US 5068440 A	HCAPLUS
Vargas	1995			US 5459164 A	HCAPLUS

L64 ANSWER 39 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688012 HCAPLUS
DN 133:247297
TI Method of treating obsessive-compulsive disorder with **sibutramine** compounds
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000056151	A1	20000928	WO 2000-US7227	20000317 <--

W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-125183P P 19990319 <--
OS MARPAT 133:247297
GI



I

AB Compds. I (R1 and R2 = H or Me) (for example, N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) or a pharmaceutically acceptable salt thereof, including individual enantiomers and racemates thereof, are used for treating obsessive-compulsive disorder. **Sibutramine** I (R1 = R2 = Me) and its metabolites I (R1 = H, R2 = Me) and I (R1 = R2 = H) inhibited the reuptake of monoamines in rat brain tissue.

IT **84467-54-9 106650-56-0, Sibutramine**

168835-59-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(obsessive-compulsive disorder treatment with **sibutramine** compds.)

IT **84485-00-7 125494-59-9 153341-22-1 154752-44-0 229639-54-7 229639-55-8 229639-56-9 229639-57-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(obsessive-compulsive disorder treatment with **sibutramine** compds.)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Gundlah	1997	283	581	J Pharmacol Exp Ther	HCAPLUS
Jeffery	1985			US 4522828 A	HCAPLUS
Nakajima	1995	17	265	Shinkei Seishin Yaku	HCAPLUS

L64 ANSWER 40 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688011 HCAPLUS
DN 133:247296
TI Method of treating premenstrual syndrome with **sibutramine** compounds
IN Mendel, Carl M.; Seaton, Timothy B.; Weinstein, Steve P.
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056150	A1	20000928	WO 2000-US7198	20000317 <--

W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRAI US 1999-125334P P 19990319 <--
OS MARPAT 133:247296
GI



I

AB Compds. I (R1 and R2 = H or Me) (for example, N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate), or a pharmaceutically acceptable salt thereof, are used for treating premenstrual syndrome. **Sibutramine** I (R1 = R2 = Me) and its metabolites I (R1 = H, R2 = Me) and I (R1 = R2 = H) inhibited the reuptake of monoamines in rat brain tissue.

IT **84467-54-9 106650-56-0, Sibutramine 168835-59-4**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating premenstrual syndrome with **sibutramine** compds.)

IT **84485-00-7 125494-59-9 153341-22-1 154752-44-0 229639-54-7 229639-55-8 229639-56-9 229639-57-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating premenstrual syndrome with **sibutramine** compds.)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Gundlah	1997	283	581	J Pharmacol Exp Ther	HCAPLUS
Jeffery	1985			US 4522828 A	HCAPLUS
Mortola	1995			Curr Opin Endocrinol	HCAPLUS

L64 ANSWER 41 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688010 HCAPLUS
DN 133:247295
TI Method of treating anxiety disorders with **sibutramine** compounds
IN Cheetham, Sharon Crawford; Heal, David John; Luscombe, Graham Paul
PA Knoll Pharmaceutical Company, USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056149	A1	20000928	WO 2000-US7125	20000317 <--
	W: AT, AU, BG, BR, CA, CN, CZ, DE, DK, ES, FI, GB, HR, HU, ID, IL, IN, IS, JP, KR, LT, LU, LV, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, TR, UA, ZA				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6355685	B1	20020312	US 2000-528063	20000317 <--
PRAI	US 1999-125161P	P	19990319 <--		

OS MARPAT 133:247295
GI



I

AB Compds. I (R1 and R2 = H or Me) (for example, N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) or a pharmaceutically acceptable salt thereof, including individual enantiomers and racemates thereof, are used for treating anxiety disorders. **Sibutramine** I (R1 = R2 = Me) and its metabolites I (R1 = H, R2 = Me) and I (R1 = R2 = H) inhibited the reuptake of monoamines in rat brain tissue.

IT **84467-54-9 106650-56-0, Sibutramine 125494-59-9 168835-59-4**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)
(treating anxiety disorders with **sibutramine** compds.)
IT **84485-00-7 153341-22-1 154752-44-0**
229639-54-7 229639-55-8 229639-56-9
229639-57-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treating anxiety disorders with **sibutramine** compds.)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Gundlah	1997	283	581	J Pharmacol Exp Ther	HCAPLUS
Jeffery	1985			US 4522828 A	HCAPLUS
Koshino	1995	17	257	Shinkei Seishin Yaku	HCAPLUS

L64 ANSWER 42 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:378080 HCAPLUS
DN 133:202953
TI Enantioselective behavioral effects of **sibutramine** metabolites
AU Glick, S. D.; Haskew, R. E.; Maisonneuve, I. M.; Carlson, J. N.; **Jerussi, T. P.**
CS Department of Pharmacology and Neuroscience (MC-136), Albany Medical College, Albany, 12208, USA
SO European Journal of Pharmacology (**2000**), 397(1), 93-102
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English
AB The anti-obesity agent, racemic (RS)-**sibutramine**, has two active metabolites, desmethylsibutramine and didesmethylsibutramine. To the extent that **sibutramine** itself mediates some of its side effects, desmethylsibutramine and/or didesmethylsibutramine might be safer and just as therapeutically effective. Because both desmethylsibutramine and didesmethylsibutramine are also optically active, the present study assessed the anorexic effects (2.5-10 mg/kg, i.p., for all drugs), in rats, of the R(+)-and S(-)-enantiomers of both metabolites and compared them to the effects of racemic **sibutramine**. Locomotor activity (2.5-10 mg/kg, i.p., for all drugs), a dopamine dependent behavior, was also measured in view of some uncertainty regarding dopaminergic effects of **sibutramine**. In view of **sibutramine**'s antidepressant profile in animal models, the same drugs were also tested in the Porsolt swim test (0.1-2.5 mg/kg, i.p., for all drugs). Lastly, the IC50s of all drugs to inhibit uptake in vitro of norepinephrine, serotonin and dopamine were determined Both (R)-enantiomers had significantly greater anorexic effects than those of their resp. (S)-enantiomers as well as of **sibutramine**. All of the agents increased locomotor activity and reduced immobilized time ("behavioral despair") in the swim test; again, the (R)-enantiomers were more potent than the (S)-enantiomers and **sibutramine**. However, the anorexic and locomotor effects could be dissociated from each other as well as from effects in the swim test. Both (R)-desmethylsibutramine and (R)-didesmethylsibutramine as well as **sibutramine** decreased food intake at a time (24-42 h post-treatment) when locomotor activity was unaffected. All of the drugs appeared to be more potent in the swim test than in the other tests and all of the drugs were more potent at inhibiting uptake of norepinephrine and dopamine than of serotonin. The results suggest that these enantioselective metabolites of **sibutramine** could be safe and effective treatments for obesity as well as possibly for depression.
IT **229639-54-7 229639-55-8 229639-56-9**
229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)

(enantioselective behavioral effects of **sibutramine** metabolites)

IT **106650-56-0, Sibutramine**
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(enantioselective behavioral effects of **sibutramine** metabolites)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Buckett, W	1988	12	575	Prog Neuro-Psychopha	HCAPLUS
Cheetham, S	1993	32	737	Neuropharmacology	HCAPLUS
Heal, D	1998	22	S18	Int J Obes	
Heal, D	1992	107	303	Psychopharmacology	HCAPLUS
Jackson, H	1997	121	1613	Br J Pharmacol	HCAPLUS
Jackson, H	1997	121	1758	Br J Pharmacol	HCAPLUS
Janowsky, A	1986	46	1272	J Neurochem	HCAPLUS
Joy, R	1967	23	589	J Appl Physiol	MEDLINE
Luscombe, G	1989	28	129	Neuropharmacology	HCAPLUS
Luscombe, G	1990	100	345	Psychopharmacology	HCAPLUS
Martin, K	1995	114		Br J Pharmacol	
Perovic, S	1995	45	1145	Arzneim Forsh Drug R	HCAPLUS
Porsolt, R	1977	266	730	Nature	HCAPLUS
Stock, M	1997	21	S25	Int J Obes	
Wise, R	1987	94	469	Psychol Rev	MEDLINE

L64 ANSWER 43 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:332323 HCAPLUS
TI First preparation of optically pure **sibutramine**: Its major metabolite and determination of absolute configuration by single X-ray analysis.
AU Fang, Q. Kevin; **Senanayake, Chris H.**; Han, Zhengxu; Morency, Cynthia; Grover, Paul; Butler, Hal; Wald, Stephen A.; Cameron, T. Stanley
CS Chemical Process Research and Development, **Sepracor** Inc, Marlborough, MA, 01752, USA
SO Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (**2000**), ORGN-197 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CLAC
DT Conference; Meeting Abstract
LA English
AB Racemic **sibutramine** was resolved with dibenzoyl L-tartaric acid, and the absolute stereochem. of **sibutramine** was determined by single X-ray crystallog. of its dibenzoyl D-tartrate. Major metabolite (Des-methylsibutramine) was obtained by demethylation of **sibutramine** with DEAD. Enantiomeric purity of **sibutramine** was determined by HPLC with Ultron ES-OVM column.

L64 ANSWER 44 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:144721 HCAPLUS
DN 132:189679
TI Methods of using and compositions comprising dopamine reuptake inhibitors
IN **Jerussi, Thomas P.**; **Senanayake, Chrisantha H.**; Fang, Qun K.
PA **Sepracor** Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 5

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2000010551 A2 20000302 WO 1999-US19167 19990823 <--
WO 2000010551 A3 20000921
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6331571 B1 20011218 US 1999-372158 19990811 <--
CA 2341441 AA 20000302 CA 1999-2341441 19990823 <--
AU 9957817 A1 20000314 AU 1999-57817 19990823 <--
EP 1107746 A2 20010620 EP 1999-945137 19990823 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
BR 9913325 A 20011002 BR 1999-13325 19990823 <--
JP 2002523366 T2 20020730 JP 2000-565873 19990823 <--
ZA 2001001498 A 20020222 ZA 2001-1498 20010222 <--
NO 2001000943 A 20010423 NO 2001-943 20010223 <--
US 2002188029 A1 20021212 US 2001-806 20011204 <--
US 6538034 B2 20030325
US 2003195261 A1 20031016 US 2003-395298 20030325 <--
PRAI US 1998-97665P P 19980824 <--
US 1998-99306P P 19980902 <--
US 1999-372158 A 19990811 <--
WO 1999-US19167 W 19990823 <--
US 2001-806 A3 20011204

AB Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an addnl. pharmacol. active compound Pharmaceutical compns. and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an addnl. pharmacol. active compound Preferred dopamine reuptake inhibitors are racemic or optically pure **sibutramine** metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred addnl. pharmacol. active compds. include drugs that affect the central nervous system, such as 5-HT3, antagonists.

IT **154752-44-0P**, (+)-**Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **153341-22-1P**, (-)-**Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **84467-54-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **229639-55-8**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **106650-56-0D, Sibutramine**, metabolites
168835-59-4 229639-54-7 229639-56-9
229639-57-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **84485-00-7P, Sibutramine** hydrochloride
153341-23-2P, (-)-Sibutramine hydrochloride
259729-88-9P 259729-93-6P 259729-95-8P
259731-39-0P 259731-40-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **106650-56-0P, Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

IT **84467-94-7P 259729-87-8P**, preparation
259729-90-3P 259729-91-4P 259729-92-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction; dopamine reuptake inhibitors, pharmaceutical compns., and therapeutic use, including with other agents)

L64 ANSWER 45 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:38891 HCAPLUS
DN 132:207624
TI First preparation of enantiomerically pure **sibutramine** and its major metabolite, and determination of their absolute configuration by single crystal X-ray analysis
AU Fang, Qun K.; **Senanayake, Chris H.**; Han, Zhengxu; Morency, Cynthia; Grover, Paul; Malone, Robert E.; Bulter, Hal; Wald, Stephen A.; Cameron, T. Stanley
CS Chemical Process Research and Development **Sepracor** Inc., Marlborough, MA, 01752, USA
SO Tetrahedron: Asymmetry (**1999**), 10(23), 4477-4480
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I

AB Racemic **sibutramine** (I, R = Me) was resolved with

dibenzoyl-D-tartaric acid, and the absolute stereochem. of **sibutramine** was determined by single crystal X-ray crystallog. of its dibenzoyl D-tartrate. The major active metabolite [desmethylsibutramine, I (R = H)] was obtained by demethylation of **sibutramine** with DEAD. The enantiomeric purity of **sibutramine** was determined by HPLC on an Ultron ES-OVM column.

IT **154752-44-0P**
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and demethylation of)

IT **259731-40-3P**
RL: PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation and x-ray anal. of)

IT **260402-77-5P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and x-ray anal. of)

IT **153341-23-2P 154752-45-1P**
RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

IT **106650-56-0, Sibutramine**
RL: RCT (Reactant); RACT (Reactant or reagent)
(resolution with dibenzoyl-D-tartaric acid)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Buckett, W	1988	12	575	Prog Neuropsychophar	HCAPLUS
Butler, D	1971	36	1308	J Org Chem	HCAPLUS
Jeffery, J	1996		2583	J Chem Soc, Perkin T	HCAPLUS
Smissman, E	1973	38	1652	J Org Chem	HCAPLUS
Young, J				WO 9400114	HCAPLUS
Young, J				WO 940047	

L64 ANSWER 46 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:749505 HCAPLUS
DN 128:70669
TI In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: **sibutramine** is a reuptake inhibitor
AU Gundlah, C.; Martin, K. F.; Heal, D. J.; Auerbach, S. B.
CS Department of Biological Sciences, Rutgers University, Piscataway, NJ, 08855, USA
SO Journal of Pharmacology and Experimental Therapeutics (**1997**), 283(2), 581-591
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English
AB Because monoamine reuptake inhibitors and releasing agents both increase extracellular neurotransmitter levels, establishing in vivo exptl. criteria for their classification has been difficult. Using microdialysis in the hypothalamus of unanesthetized rats, we provide evidence that serotonin- (5-HT) selective and nonselective reuptake inhibitors can be distinguished from the 5-HT-releasing agent fenfluramine by four criteria: (1) Systemic fenfluramine produces a much greater increase in 5-HT than the reuptake inhibitors. (2) The 5-HT somatodendritic autoreceptor agonist, (±)-8-hydroxy(dipropylamino)tetralin (8-OH-DPAT), attenuates the increase in 5-HT produced by reuptake inhibitors, but not by fenfluramine. (3) The large increase in 5-HT produced by infusion of reuptake inhibitors into the hypothalamus is attenuated by their systemic administration. However, systemic injection of fenfluramine during its

local infusion does not attenuate this increase. (4) Reuptake inhibitor pretreatment attenuates fenfluramine-induced increases in 5-HT. According to these criteria, the in vivo effects of the novel antiobesity drug **sibutramine** are consistent with its characterization as a 5-HT reuptake inhibitor and not a 5-HT releaser. Thus, **sibutramine** produced increases in hypothalamic 5-HT similar in magnitude to the effects of the known reuptake inhibitors, and the increase was attenuated by 8-OH-DPAT. Also, **sibutramine** attenuated fenfluramine-induced 5-HT release. Systemic administration of **sibutramine** failed to attenuate the increase in 5-HT produced by its local infusion, suggesting that this criterion is not applicable to compds. with low affinity for the 5-HT transporter.

IT **106650-56-0, Sibutramine**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(in vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents in relation to **sibutramine**, a reuptake inhibitor and fenfluramine, a releasing agent)

L64 ANSWER 47 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:713861 HCAPLUS
DN 126:143907
TI Synthesis of sibutramine, a novel cyclobutylalkylamine useful in the treatment of obesity, and its major human metabolites
AU Jeffery, James E.; Kerrigan, Frank; Miller, Thomas K.; Smith, Graham J.; Tometzki, Gerald B.
CS Knoll Pharmaceuticals, Res. Development Dep., Nottingham, NG1 1GF, UK
SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1996), (21), 2583-2589
CODEN: JCPRB4; ISSN: 0300-922X
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 126:143907
GI



I

AB Synthetic routes to N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine (sibutramine) 1 (= I) and its demethylated and hydroxylated human metabolites N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine 2, 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine 3, 4-amino-4-[1-(4-chlorophenyl)cyclobutyl]-2-methylbutan-1-ol 4 and c-3-(1-amino-3-methylbutyl)-3-(4-chlorophenyl)cyclobutan-r-1-ol 5a are described. Key steps are tandem Grignard-reduction reactions on 1-(4-chlorophenyl)cyclobutanecarbonitrile 7 and its 3-(tetrahydropyran-2-yloxy)-substituted analog 14 and a convenient one-pot conversion of 4-chlorophenylacetonitrile 6 into the 1-(4-chlorophenyl)-3-hydroxycyclobutanecarbonitrile 13.

IT **186521-83-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of sibutramine and its major human metabolites with tandem Grignard-reduction reactions of 1-(4-chlorophenyl)cyclobutanecarbonitrile and cycloalkylation of 4-chlorophenylacetonitrile as key steps)

IT **186521-84-6P 186521-90-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis of sibutramine and its major human metabolites with tandem Grignard-reduction reactions of 1-(4-chlorophenyl)cyclobutanecarbonitrile and cycloalkylation of 4-chlorophenylacetonitrile as key steps)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Armitage, B	1984			BP 2128991	
Bogatskii, A	1974	4	49	Vopr Stereokhim	HCAPLUS
Bray, G	1994	18	60	Int J Obes	
Bray, G	1990		639	Progress in Obesity	
Buckett, W	1988	12	575	Prog Neuro-Psychopha	HCAPLUS
Butler, D	1971	36	1308	J Org Chem	HCAPLUS
Cahiez, G	1978		3013	Tetrahedron Lett	HCAPLUS
Clarke, H	1933	55	4571	J Am Chem Soc	HCAPLUS
Corbel, B	1976	41	3648	J Org Chem	HCAPLUS
Courtois, G	1983		21	Bull Soc Chim Fr	HCAPLUS
Drouin, P	1994	18	60	Int J Obes	
Harris, P	1988	13	736	Drugs of the Future	
Horning, D	1970	48	975	Can J Chem	HCAPLUS
Housley, J	1991			US 5047432	HCAPLUS
Jones, S	1994	18	61	Int J Obes	
Kelly, F	1994	18	61	Int J Obes	
Kopelman, P	1991	45	234	Br J Clin Pract	MEDLINE
Kotsuki, H	1990		401	Synthesis	HCAPLUS
Kozlik, A	1982			BP 2098602	
Kozlik, A	1984			BP 2127819	
Luscombe, G	1989	28	129	Neuropharmacology	HCAPLUS
Mendels, J	1994	18	61	Int J Obes	
Moore, M	1941	5	301	Org React, (N Y)	
National Institutes Of	1985	103	1073	Ann Intern Med	
Royal College Of Physic	1983	17	3	J R Coll Physicians	
Silverstone, T	1992	43	820	Drugs	MEDLINE
Weiberth, F	1986	51	5338	J Org Chem	HCAPLUS
Weintraub, M	1991	50	330	Clin Pharmacol Ther	MEDLINE

L64 ANSWER 48 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:280290 HCAPLUS
DN 120:280290
TI Methods and composition for treating depression and other disorders using optically pure (+)**sibutramine**
IN Young, James W.
PA **Sepracor** Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 9400047	A1	19940106	WO 1993-US5967	19930622	<--
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA					
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
	AU 9345429	A1	19940124	AU 1993-45429	19930622	<--
	JP 07508281	T2	19950914	JP 1993-502537	19930622	<--
	EP 708639	A1	19960501	EP 1993-915449	19930622	<--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
PRAI	US 1992-903034	A	19920623	<--		
	WO 1993-US5967	A	19930622	<--		

AB Methods and compns. are disclosed utilizing the optically pure (+) isomer

of **sibutramine**, which is a potent drug for treatment of depression, Parkinson's disease, cerebral function disorders, obesity, dementia and related disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. Further, methods and compns. are disclosed utilizing optically pure (+) **sibutramine** in order to avoid the adverse effects associated with the administration of racemic **sibutramine**.

IT **154752-44-0**, (+)-**Sibutramine** **154752-45-1**, (+)-**Sibutramine** hydrochloride
RL: BIOL (Biological study)
(antidepressant)

L64 ANSWER 49 OF 49 HCAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:144170 HCAPLUS
DN 120:144170
TI Pharmaceutical compositions for treating depression and other cerebral disorders containing optically pure (-) **sibutramine**
IN Young, James W.
PA **Sepracor** Inc., USA
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9400114	A1	19940106	WO 1993-US5966	19930622 <--
	W: AU, BB, BG, BR, BY, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9345428	A1	19940124	AU 1993-45428	19930622 <--
	EP 647134	A1	19950412	EP 1993-915448	19930622 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08500093	T2	19960109	JP 1993-502536	19930622 <--
	AU 9745298	A1	19980205	AU 1997-45298	19971121 <--
	AU 721924	B2	20000720		
	AU 696392	B2	19980910	AU 1997-48297	19971211 <--
	AU 9748297	A1	19980219		
PRAI	US 1992-903040	A	19920623 <--		
	US 1992-903034	A	19920623 <--		
	WO 1993-US5966	A	19930622 <--		

AB Pharmaceutical compns. containing optically pure (-) **sibutramine** (I), are used for treatment of depression and other cerebral function disorders, as well as other conditions related to the activity of the compound as an inhibitor of the neuronal reuptake of monoamines. I is free of the adverse effects associated with the administration of racemic **sibutramine**. A capsule contained I 10, lactose 70.0, corn starch 19.5, Mg stearate 0.5 mg.

IT **153341-22-1**, (-)**Sibutramine** **153341-23-2**, (-)**Sibutramine** hydrochloride
RL: BIOL (Biological study)
(pharmaceutical compns. containing, for treatment of depression and cerebral function disorders)

=>